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CHAPTER I 
 
INTRODUCTION 
 
Inflammation 
 An integral aspect of the innate immune response of cells is the initiation of inflammation. 
Inflammation is a process characterized by rapid accumulation of immune cells within designated 
areas with the goals of isolating sites of injury, protecting the organism from potentially harmful 
threats, and triggering the healing process.1 Inflammation is initiated and resolved by a series of 
complex, microscopic events such as changes in regulation of lipid mediators, vascular 
permeability, and cell recruitment and migration.2 
 Inflammation can be divided into two distinct types based on the length of time during 
which it is activated within cells. Acute inflammation, the body’s immediate response to injury, is 
an essential step in the healing process and a protective response to threats or injury. It is 
characterized by pain, redness, swelling, and heat in the afflicted area. However, this response can 
be transposed to the second type of inflammatory immune response, chronic inflammation. 
Chronic inflammation, the body’s long-term healing byproduct, is traditionally associated with a 
variety of diseases such as cardiovascular disease, asthma, and rheumatoid arthritis (RA).3 
Recently, researchers have demonstrated connections between chronic inflammation and a number 
of diseases such as Alzheimer’s, certain types of cancer, and diabetes. The chronic inflammatory 
mechanisms identified in these disorders are fibrosis, metaplasia, and tumor formations.4 
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Initiation of Inflammation 
Inflammation is viewed as a complex pathophysiological process that involves hundreds 
of mediators and differing cell types and tissues. It is initiated by any stimulus that cells identify 
as a threat. This complexity of mechanism and daunting variety of triggering events makes 
elucidation of specific processes difficult. For example, inflammation can be initiated by the 
recognition of foreign material by Immunoglobulin (Ig) E antibodies, a relatively common 
phenomenon. Activated IgE then binds with high affinity to receptor FCԐRI in mast cells (MC) and 
basophils, which initiates a series of pathways that include post-translational modifications of 
signaling proteins responsible for releasing calcium ions (Ca2+) from intracellular storage.5 FCԐRI 
activation also results in the degranulation of cytoplasmic granules containing the pro-
inflammatory mediators, an increase in production of eicosanoids, and secretion of cytokines and 
chemokines. These signaling molecules start cascading events that result in altered blood flow, 
increased vascular permeability, and constriction of bronchiole muscles.6 The excess of the 
inflammatory mediators shifts the physiological manifestations into the symptoms of airborne 
allergies and asthma. 
Inflammation can also be initiated by the classic complement pathway. Antibody IgG and 
IgM bind directly to antigens, which leads to antibody aggregation. Antibody aggregation begins 
the formation of the complement complex.7 This complex is cleaved into individual proteins or 
peptides that are deposited in the injured tissues. The cleavage products activate the release of pro-
inflammatory cytokines from phagocytes. In RA, B-cells and other inflammatory cells that have 
been activated by the complement pathway infiltrate the synovial membrane and release tumor 
necrosis factor alpha (TNF-α), interleukin-1 (IL), and IL-6. These pro-inflammatory mediators 
increase cell recruitment to the site of inflammation, causing the potential for harm to the tissue to 
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increase significantly. Without resolution, phagocytosis, or apoptosis, such tissues will experience 
serious damage.8 In RA, cell accumulation leads to the synovial lining becoming hyperplastic and 
expanding, which causes bone and cartilage degradation.9 Pattern recognition receptors can also 
activate the complement cascade by recognizing specific antigen-antibody complexes, facilitating 
the process of initiating inflamation.10 
 
Eicosanoids 
Eicosanoids are a group of lipid mediators of inflammation that have been extensively 
studied over the last 50 years. They act locally as signaling molecules at nanomolar concentrations 
on their target cells. Granulocytes, macrophages, neutrophils, platelets, MCs, and endothelial cells 
are involved with eicosanoid production during inflammation.3 In addition to being heavily 
involved in initiating inflammation, eicosanoids are integral to the process of resolving 
inflammation. Inflammation resolution is the return of tissues to normal equilibrium and function, 
a process that is as complicated as inflammation initiation, but is not as thoroughly understood. 
Critical steps in resolution performed by eicosanoids are propagation of leukocyte apoptosis, 
limitation of the synthesis of cellular adhesion molecules, recruitment and activation of 
macrophages for phagocytosis, and modulation of pro-resolving mediators.11  
 
Discovery of Eicosanoids and Early Research  
Eicosanoids have been a focus of scientific research since their discovery, and the 
knowledge base for the full range of their impact on biological functions remains incomplete. The 
importance of these signaling molecules was initially discovered by George and Mildred Burr in 
1930 when they observed that rats with fat-free diets experienced reproductive disturbances, 
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growth hindrance, scaly skin, kidney lesions, and excess water consumption. The Burrs were the 
first to coin the term “essential fatty acids” and published their results stating that fats were not 
just necessary for calorie consumption, as previously thought, but for a variety of biological 
pathways.12,13 Around the same period, two other research groups discovered that lipid extracts 
from seminal plasma and sheep’s vesicular glands had vasodepressor and smooth muscle-
stimulation effects.14,15 The identified lipids were called prostaglandins. It took another 30 years 
before the implications of these individual observations were integrated by Bergstrӧm and 
Samuelsson.16 They demonstrated the chemical structure of “classic” prostaglandins and that 
prostaglandins were biosynthesized from the essential fatty acids, arachidonic acid (AA) and 
dihomo-γ-linolenic acid. Today the members of the eicosanoid family include virtually all long-
chain oxygenated products from AA, whether formed enzymatically or nonenzymatically.17 
Humans ingest/synthesize over 7 fatty acids that are substrates for human lipoxygenases (LOX), 
cyclooxygenases (COX), and cytochrome P450 (CYP). These 7 fatty acids are enzymatically 
converted to oxylipins. Eicosanoid is derived from the Greek world for twenty, eikosi, since their 
first identified precursor lipid, AA, has a 20-carbon chain. 
 
 
Figure 1. Polyunsaturated fatty acid (PUFA) chemical structures. Chemical structure of the 
most common PUFAs converted to oxylipins in mammalians (AA) and in plants (linoleic acid 
(LA)). AA is an omega-6 fatty acid with a 20-carbon chain and four cis double bonds. LA is also 
an omega-6 fatty acid with an 18-carbon chain and two cis double bonds.  
 
AA LA 
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Eicosanoid Biosynthesis  
Eicosanoids behave similarly to hormones in terms of their ability to initiate and resolve 
cellular functions at nanomolar concentrations. However, unlike hormones, eicosanoids are not 
transported by the circulatory system for distal effects.17 Therefore, physiology utilizes eicosanoids 
for potent, local effects on signaling pathways rather than as an inter-systemic messenger.  
Hundreds of structurally and stereochemically unique eicosanoids can be generated by the 
metabolism of LA, AA, and other less abundant essential fatty acids such as dihomo-γ-linolenic 
acid, which is derived from LA, and eicosapentaenoic acids (EPA), which are derived from α-
linolenic acid.18,19 Some of the more commonly investigated types of eicosanoids are 
prostaglandins and thromboxanes, formed by COX superfamily members, leukotrienes (LTs) and 
lipoxins (LXs) formed by LOX superfamily, and epoxyeicosatrienoic acids which are formed by 
the CYP superfamily.20  
Relatively few of the eicosanoids have their physiological role identified, but some have 
been observed to play a role in vasodilation, muscle contraction, inflammation propagation and 
resolution, and pain response.2 The type and concentration of eicosanoids biosynthesized by tissue 
is dependent on the type of cell, the tissue location, and the activation state of the cell. Some 
eicosanoids, such as prostaglandins, are synthesized in most cell types and in most tissues, but the 
identity and degree of prostaglandins produced varies depending on local conditions. For example, 
in macrophages, the type of specific prostaglandin as well as their concentration after cell 
stimulation show significant differences based upon the progenitor tissue. Differences in 
prostaglandin production also exist between primary macrophages and transformed 
macrophages.21 A further wrinkle in the differing processes is observed by intra-cellular alterations 
of eicosanoid type produced depending on the activation state. For example, resting macrophages 
 6 
 
synthesize thromboxanes over classic prostaglandins. This changes after cellular activation by 
bacterial lipopolysaccharide (LPS) or complement cleavage product C3b.22,23 These observations 
indicate a high level of eicosanoid regulation. This is hypothesized to be a necessary cellular 
function as over expression of eicosanoids can cause damage to their surrounding tissue. 
Given their clinically relevant inflammatory properties, eicosanoids are pharmaceutical 
targets. Currently the most prevalent therapeutic on the market for regulation of eicosanoids is for 
inhibition of prostaglandin synthesis by nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs 
non-selectively bind to COX isoform-1 (COX-1) and COX isoform-2 (COX-2) to prevent 
oxygenation of AA. Limiting prostaglandin biosynthesis is problematic as prostaglandins are 
important signaling molecules in several physiological pathways. In addition, NSAIDS can have 
adverse gastrointestinal effects.24 These treatments, however, are only one approach to eicosanoid 
regulation, prompting further research to form a complete understanding of the inflammatory 
process and the mechanisms by which it can be regulated. This literature review will focus on the 
eicosanoids, LTs, LXs, and resolvins (Rv), and the enzymes involved with their biosynthesis and 
regulation. These specific eicosanoids are identified to have essential pro- and anti-inflammatory 
properties, and thus are of particular note. 
 
Leukotrienes 
LTs are primarily synthesized in inflammatory cells such as polymorphonuclear (PMN) 
leukocytes, macrophages, MCs, and dendritic cells (DC).11 These cells can be activated by a 
variety of stimuli such as IgE-antigen complexes, TNF-α, and increased concentration of 
ionophores.25 Cellular activation most notably results in an increase in Ca2+ concentrations in the 
cytosol. The increase in Ca2+ directly initiates the biosynthesis of LTs. The correlation between 
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LTs biosynthesis and Ca2+ concentration was first demonstrated in the 1970s in rabbit PMNs and 
mouse mastocytoma cells.26,27,28 Ca2+-stimulation of LT biosynthesis was also described in rat 
basophilic leukemia (RBL) cells when an increase in ionophore A23187 (a mobile divalent ion 
carrier) resulted in increased production of 5-hydroxyeicosatetraenoic acid (5-HETE).29 5-HETE 
is a metabolized product of 5-hydroperoxyeicosatetrenoic acid (5-HpETE), which is the precursor 
molecule for LT synthesis.  
 
LT Biosynthesis 
Ca2+ ions will bind to both cytosolic phospholipase A2 (cPLA2) and 5-LOX causing them 
to translocate from the cytosol to the nuclear membrane.30,31 Two or three Ca2+ ions bind to the C2 
domain in cPLA2 and to the polycystin-1, lipoxygenase, α-toxin (PLAT) domain in LOXs. Ca2+ 
concentrations between 4-10 µM are required for full activation of 5-LOX in intact cells.32  When 
transported to the nuclear membrane, cPLA2 catalyzes the hydrolysis of the sn-2 acyl bond in 
phospholipids to generate free AA.33 5-LOX will form a protein complex with 5-lipoxygenase 
activating protein (FLAP) at the membrane when it translocates to the nuclear membrane.34 It is 
hypothesized that free AA generated by cPLA2 is facilitated from the membrane to 5-LOX by 
FLAP. AA is oxygenated at the C-5 position by 5-LOX to generate 5-HpETE. 5-HpETE is either 
enzymatically reduced to form 5-HETE or 5-LOX will convert 5-HpETE to LTA4, an unstable 
epoxide intermediate.35  
LTA4 can be metabolized by two pathways. It can be hydrolyzed by LTA4 hydrolase 
(LTA4H) to form LTB4 or it can be conjugated to glutathione by LTC4 synthase  (LTC4S) to form 
LTC4.
2 LTA4H is distributed in the cytosol of almost all mammalian cells. LTC4S is an integral 
membrane protein expressed in eosinophils, MCs, and monocytes.36 The tripeptide moiety of LTC4 
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can be hydrolyzed to generate LTD4 by γ-glutamyl transpeptidase (GGT) and then LTD4 can be 
hydrolyzed by several dipeptidases to form LTE4 (Figure 2).
37 These LTs are called cysteinyl-
leukotrienes (cys-LT) and are identified as slow-reacting molecules of anaphylaxis. 
Figure 2. LT biosynthesis. Free AA is oxygenated and subsequently hydrolyzed by 5-LOX in 
complex with FLAP to form LTA4. LTA4 is either hydrolyzed by LTA4H to generate LTB4 or 
conjugated to GSH to form LTC4. LTC4 is further metabolized to form the additional cys-LTs, 
LTD4 and LTE4.    
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Biological Mechanisms of LTs  
LTs are identified as pro-inflammatory mediators that act by binding to four different G-
protein-coupled receptors (GPCR).11 LTB4 has a high affinity for leukocyte LTB receptor-1 
(BLT1). This receptor is coupled to Gq protein which has an α-subunit that binds and induces 
activity of phospholipase C. Phospholipase C cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) 
to form D-myo-inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) both of which are 
potent signaling molecules in inflammation.38 High concentrations of LTB4 are required for LTB4 
to bind to LTB receptor-2 (BLT2), which signals through similar pathways to BLT1. The 
remaining GPCRs are the cys-leukotriene receptors, CysLT1, CysLT2, and CysLT3.39,40  
LTs have differing effects on inflammatory cells depending on LT type and cellular stimuli. 
In DCs, increased concentration of LTC4 results in increased C-C chemokine receptor type 7, a 
chemokine that promotes DC migration through extracellular matrix to sites of injury.41 In 
lymphocytes, responses to LT are dependent on the type and amount of lymphocytes present. For 
example, in lymphocyte cell cultures infected with Epstein-Barr virus LTB4 inhibited B-cell 
proliferation. In vivo experiments indicated LTB4 played a role in directing T-cell migration.
42 
LTs are associated with the pathogenesis of several inflammatory or autoimmune diseases. 
RA is caused by severe inflammation of joints that eventually leads to destruction of bone and 
cartilage. Inhibiting the synthesis of LTB4 protected mouse models of RA from erosion of bone 
and influx of inflammatory cells.43 Cys-LTs were originally called “slow reacting substance of 
anaphylaxis” due to their potent bronchoconstrictor activity.28 Excess Cys-LTs results in the 
clinical manifestation of asthma and allergic responses, bronchial spasms, diarrhea, and blood 
pressure variations.3 
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Lipoxins 
Resolution of inflammation has historically been viewed as a passive process, occurring as 
a result of the withdrawal of pro-inflammatory signals, such as LTs and prostaglandins. LXs were 
the first eicosanoid subgroup that were shown to actively resolve inflammation.11 The resolution 
of acute inflammation is complex, as it involves several cellular pathways occasionally acting 
simultaneously. One crucial step in resolution is cell clearance, which is accomplished by 
apoptosis of leukocytes and limiting cell adhesion. The regulation of the resolution rate is also an 
indispensable process. Inflammation resolution is mediated by recruitment of macrophages that 
complete phagocytosis of the microbes and apoptotic cells.44 Without this process the 
accumulation of cells results in tissue and organ damage. LXs have been observed to play 
important roles in all of these pathways, the details of which will be discussed below. 
 
LX Biosynthesis 
LX biosynthesis requires interacting LOXs and the proximity of specific cells. Moreover, 
in some occurrences the metabolites are transferred to another cell for metabolism. There are two 
main pathways for LX synthesis. In the first pathway, 5-LOX catalyzes the conversion of AA to 
LTA4 similar to the first step in LT synthesis. LTA4 is then transferred to adjacent platelets and is 
converted to LXA4 or LXB4 by the oxygenation from 12-LOX.
45 In the second pathway, AA is 
converted to 15-HpETE in the endothelium by 15-LOX. 15-HpETE is subsequently taken up by 
PMN cells or monocytes and oxygenated by 5-LOX to form the 5,6-epoxytetraene intermediate. 
This short lived intermediate is hydrolyzed to generate LXA4 or LXB4.
46 Alternatively, there is a 
pathway to produce 15-epimer-LXs that is triggered by acetylated COX-2. When COX-2 is 
acetylated by acetylsalicylic acid (aspirin) the catalytic product is altered to 15(R)-HpETE as 
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opposed to the 15(S)-HpETE product formed by 15-LOX. 15(R)-HpETE is oxygenated by 5-LOX 
to form 15(R)-LXA4.
47 Aspirin triggered LXs are twofold more potent than the 15(S)-LXs formed 
by the classic pathway.44 
 
 
Figure 3. LXs Biosynthesis. LXs are synthesized through 2 main pathways by LOX oxygenation 
and sequential hydrolase activity. LX are the first eicosanoids identified to play a role in resolution 
of inflammation.    
 
Biological Pathways of LXs 
LX research has so far yielded conflicting results. The variances in experimental 
conclusions are proposed to be due to a lack of positive control for LXA-induced responses.48 
Research suggests that LXs resolve inflammation through several pathways. LXs biological effects 
are produced by binding to formyl-peptide receptor-2, also referred to as FPR2/ALX due to its 
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interaction with LXs.49 In DCs, LXs inhibit the productions of IL-2, an important cytokine in the 
immune response.50 In addition, LXA4 has been identified to resolve bronchial constriction in 
murine models of asthma. Administration of a stable analog agonist for LXA4 receptors resulted 
in decreased leukocyte recruitment and a decrease in the pro-inflammatory mediators, IL-5, IL-13, 
prostanoids, and cys-LTs.  Transgenic expression of human LXA4 receptors in murine leukocytes 
resulted in inhibition of pulmonary inflammation and eicosanoid-initiated eosinophil tissue 
infiltration.51 LXA4 has also been observed to increase natural killer cell mediated eosinophil 
apoptosis and decreased IL-13 release by type 2 innate lymphoid cells.52 Combining these 
observations leads to the overall conclusion that LXs initiate the resolution of inflammation. 
However, additional studies are needed to clarify the cellular pathways directly affected.  
 
Resolvins 
Rv are another class of anti-inflammatory mediators that have recently been identified. Rv 
names are derived from their identification as “inflammation resolution interaction products”.19 
They can be classified as either a D-series, meaning the Rv was derived from docosahexaenoic 
acid (DHA)19, or E-series, which are derived from EPA.18 Both DHA and EPA are naturally 
occurring omega-3 fatty acids. The biosynthesis of Rv E-series is initiated by the conversion of 
EPA by CYP. The resulting intermediate is then either oxidized by 5-LOX in leukocytes to form 
RvE1, or can be reduced to form RvE2.53 Similarly to LXs, an aspirin triggered epimer has been 
identified with EPA initially transformed by acetylated COX-2.   
Biosynthesis of D-series of Rv is similar to the E-series in which DHA is converted by 
either acetylated COX-2 or CYP to a stereoselective intermediate. This intermediate is 
enzymatically converted by 15-LOX to form either RvD1-4 or (R)-RvD1-4 depending on which 
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intermediate is utilized.54 Knowledge on Rvs biological function and receptors is in the early stages 
of development. Currently, RvE1 is known to interact with either receptor Chem R23 or BLT1 to 
mediate cell-type specific effects.55,56 Protein-ligand interaction screening also revealed 
FPR2/ALX and orphan receptor GPR32 as potential receptors for RvE1.57 The receptor for RvE2 
has not been characterized, but its pro-resolving actions are mediated by a GPCR in leukocytes. 
RvE series has been shown to be a potent mediator in regulating chemotaxis of human neutrophils, 
enhancing phagocytosis, and increasing anti-inflammatory cytokine production.58 RvD series has 
been observed to limit PMN infiltration in a dose-dependent manner.59 The continued discoveries 
of new eicosanoids and their roles in cellular pathways indicate a continued need for research on 
these signaling molecules and the enzymes that complete their metabolism. 
 
The Lipoxygenase Superfamily 
The enzymatic products of LOXs are crucial in both the propagation and resolution of 
inflammation, a process which brands LOXs as therapeutic targets by pharmaceutical companies. 
The only drug in active use that targets LOXs is Zileuton. Zileuton is an inhibitor of 5-LOX that 
regulates leukotriene biosynthesis. However, Zileuton currently suffers from clinical limitations 
such as short half-life and potential liver toxicity. These complications have necessitated that 
patients take several daily dosages rather single daily supplements. They also have to complete 
frequent liver-function tests.60 Atreuloton is a 5-LOX reversible inhibitor that is currently under 
clinical trials. However, it is currently unavailable for patients and must be researched further once 
clinical trials are completed.61 Alternative pharmaceuticals for regulating LT and LX biosynthesis 
need to be investigated. An essential step in this investigation could be the development of an 
extensive knowledge base on LOX structure and function. 
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LOXs are a superfamily of non-heme iron-containing dioxygenases that catalyzed the 
oxygenation of PUFAs that contain a series of cis-double bonds.62 LOXs are expressed in a variety 
of cells among animals, plants, and fungi.63 Until recently, LOXs were thought to be found only 
in eukaryotes, however, LOX sequences have now been detected in prokaryotic organisms, mainly 
in gram-negative bacteria. Their biological function in bacteria has yet to be identified.64 The 
expression levels of LOXs significantly vary depending on the organism and the LOX homolog. 
For example, 12- and 15-LOX have relatively low expression in mammalian skin65 and relatively 
high expression in rabbit reticulocytes.66 The biological importance of their enzymatic products 
(LTs, LXs, and Rvs) have already been discussed.  
In addition, some homologs of LOXs are believed to play supplementary roles in cells. A 
precursor screen of lipids extracted from ionophore-treated IL-4-induced human monocytes 
identified four intact phospholipids that were oxidized by 15-LOX.67 Clustering of oxidized 
phospholipids is thought to result in a “hydrophilic pore” that disrupts the barrier function of the 
cellular membrane. The lipid hydroperoxides (LOOH) produced by LOX catalysis have also been 
implicated in regulating the cellular redox state, which may lead to increased or decreased 
expression of redox sensitive genes.62 
 
LOX Nomenclature  
Historically LOXs are named according to the specific position of oxygenation of their 
most common substrate (AA in mammalians and LA in plants) as counted from the carboxyl of 
the fatty acid (Figure 4). For example, human 15-LOX oxygenates the fifteenth carbon on AA to 
produce 15-HpETE. If the LOX is stereochemistry-specific the name will also identity the 
stereospecific product (e.g. 12S-LOX or 12R-LOX). This naming system can lead to some 
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confusion due to the differing lengths of the common substrates across species. The plant LOX 
corresponding to human 15-LOX is 13-LOX due to the shorter carbon chain in LA compared to 
AA. Additional confusion arises when there are multiple LOXs in the same species with differing 
primary sequences that yield the same enzymatic products. For example, mammalian 12-LOXs 
are named for the prototypical tissues in which they are expressed, such as platelet 12-LOX and 
leukocyte 12-LOX. In addition, some LOXs form more than one HpETE isomer, leading a mixture 
of products. This results in names such as 12/15-LOX (also called 15-LOX-1). 
 
Figure 4. LOXs oxygenation sites on AA. AA has three pentadiene moieties creating six possible 
hydrogens for abstraction. The hydrogens are labeled different colors with the corresponding 
oxygenation products in the same color.  
 
LOX catalytic mechanism and product specificity 
All LOXs initiate, control, and terminate a free radical reaction between a substrate fatty 
acid and molecular oxygen (Figure 5). The catalytic cycle begins by activation of the enzyme 
through oxidation of the catalytic iron in the active site (Fe2+ to Fe3+). This oxidation is proposed 
to be completed by discrete concentrations of LOOHs in the cell. In vitro assays show a decrease 
in the lag phase of LOX enzyme kinetics, corresponding to increased concentrations of LOOHs.68 
The active state of the catalytic iron is coordinated with a hydroxide ion. After iron activation, the 
substrate enters the active site and is positioned in a regio- and stereo- specific orientation by 
5S 
5R 
9S 
9R 
11S 
11R 
15S 
15R 
8S 
8R 
12S 
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hydrophobic amino acids side chains. In the active site, a proton-coupled electron transfer takes 
place on the allylic carbon in the pentadiene moiety with an electron from the substrate’s hydrogen 
entering the d-orbital of the iron and the proton from the hydrogen transferred to the hydroxide ion 
coordinated to the iron to form water.  From there, the substrate becomes a lipid radical that will 
undergo delocalization and allow molecular oxygen to attack on the substrate face opposing the 
proton-coupled electron transfer.69 The iron then donates an electron to the O2 on the substrate. 
The O2 will abstract the hydrogen from the iron-water complex allowing the HpETE product to 
form and restoring the iron’s active state. 
                     
 
Figure 5. The catalytic cycle of LOXs. The catalytic iron is activated by LOOHs. A proton-
coupled electron transport forms a lipid radical that is attacked by molecular oxygen. Catalysis by 
LOXs requires the iron to switch redox states multiple times.  
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  There are three possible pentadiene moieties on AA for LOX oxygenation leading to six 
possible reaction sites and two possible stereospecific conformers per site. Therefore, twelve 
unique products can be produced from AA by different LOXs oxygenation. In nature, there are 
enzymes specific for 10 of the 12 available sites on AA (5R, 5S, 8R, 8S, 9R, 11R, 11S, 12R, 12S, 
and 15S).70 While the enzymatic mechanism for LOXs is well understood, the structural basis for 
product specificity remains complicated and ambiguous. The current understanding of product 
specificity involves three different aspects: (1) channel depth that positions the fatty acid; (2) the 
head-to-tail orientation of the fatty acid; and (3) the access site of molecular oxygen. Channel 
depth involves shifting the fatty acid so that a different pentadiene moiety has the allylic hydrogen 
abstracted (a frameshift). The impact of channel depth in LOXs was first observed when a M419V 
site mutation in 15-LOX-1 changed the ratios of HpETE products.71 Site mutagenesis studies that 
reduce the substrate channel depth in 11R-LOX revealed no change in substrate affinity, but did 
result in product variation and decreased turnover rate.72 The alteration between head-to-tail 
orientation was first contemplated when it was observed that plant 9S-LOX and 13S-LOX 
abstracted the pro-R and pro-S hydrogen from the same carbon on LA.73 The 9S- and 13S- 
positions on LA are on opposite faces of LA, which indicates that the substrate was simply in the 
opposite head to tail orientation in the active site. The molecular oxygen channel to the active site 
is hypothesized to be controlled by a single amino acid in the active site. Mutagenesis studies 
indicate that an alanine conserved in most S-LOXs and a glycine conserved in most R-LOXs are 
important in directing the molecular oxygen to the pentadiene on the substrate.74 Mutation of 
alanine to glycine in S-LOX resulted in generation of R-HpETE product.  
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Structural Analysis of Lipoxygenases 
In addition to sharing catalytic mechanisms, LOXs share many structural features. The first 
LOX structure, LOX-1 isoform from soybean, was identified in 1993.75 The structure established 
common elements that have been observed in all subsequent LOX structures, even though plant 
LOXs generally have a longer primary sequence (approximately 900 amino acids, while 
mammalian have approximately 650 amino acids). LOXs have two domains, the catalytic domain 
and the PLAT domain, with the exception of a recently published structure from P. aeruginosa.76 
Bacterial LOXs appear to lack the PLAT domain and have additional helices that cap the catalytic 
subunit in its place. 
In all mammalian LOXs, the catalytic domain is composed of approximately 17 α-helices 
and crystal structures indicate a roughly parallel orientation for the majority of the helices.77 At 
the center of the catalytic domain is the active site which houses the catalytic iron. This iron is 
coordinated by invariant histidines, the C-terminal carboxyl group, and a water molecule.78 Use of 
the C-terminal carboxyl group as part of the active site is an uncommon and quite remarkable 
feature in LOXs. The terminus is allowed to enter the protein core by irregularities in helices 
structures. The C-terminus is frequently a conserved isoleucine, but the role of the isoleucine side 
chain is unknown. The nonpolar bonds in the side chain have limited van der Waals interactions 
with the helices that form the active site. However, a crystal structure of 8R-LOX from 
Pseudomonas aeruginosa suggest this area of the active site is highly solvated due to an intricate 
network of water molecules leading to the active site, indicating there is not a tight association 
between the helices and the side chain of isoleucine.76  
A high degree of flexibility in the tether linking the catalytic and PLAT domain was 
indicated by small angle x-ray scattering experiments, however, to date every LOX crystal 
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structure has conformed to the same domain orientations suggesting an extensive domain 
interface.79 The PLAT domain was originally known as a “C2-like” domain due to its structural 
and functional similarity to the Ca2+-dependent, membrane-binding domains in phospholipases. 
The domain has a high degree of structural conservation amongst LOXs, but the sequence 
similarity is low. A 45Ca2+ overlay binding assay in 5-LOX originally indicated the PLAT to be 
the Ca2+ binding domain.80 The amino acids identified to coordinate the binding of Ca2+ are not 
conserved throughout the superfamily. The PLAT domain is also identified to be essential for 
membrane association. However, studies indicate the PLAT domains in different LOXs isoforms 
may have differences in phospholipid preference upon membrane association.81,82 The PLAT 
domain was previously thought to play a role only in membrane association, although recent 
evidence indicates this domain may play several roles in LOX function. Eek et al. have suggested 
a π-cation interaction between an invariant tryptophan on the PLAT domain, and a lysine or 
arginine in the catalytic domain.72 This interaction would constitute a connecting site between the 
Ca2+ binding loops and α-helix 2, which is part of the external side of the active site. Currently, 
there is no structural evidence for a connection between the PLAT domain and substrate binding. 
However, a crystal structure of truncated 12S-LOX (lacking PLAT domain) revealed significant 
positional shifts in α-helix 2 upon removal of the PLAT domain, implying that a physical restraint 
imposed by the domain may play a role in positioning α-helix 2.83 In addition, mutations involved 
in inter-domain interactions in rabbit 12/15-LOX resulted in a decrease in both catalytic activity 
and protein stability.84 
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5-Lipoxygenase 
A significant amount of research has been focused on 5-LOX due to its role in LT 
biosynthesis. In this work preliminary steps in identifying 5-LOX protein and ligand interactions 
are completed. 5-LOX is primarily expressed in cells of myeloid origin such as neutrophils, 
eosinophils, MCs, basophils, and monocytes. To ensure the inflammatory response is appropriately 
matched to the cellular threat, cells have evolved a complex series of cellular and molecular 
controls to regulate 5-LOX enzymatic activity. Optimal activity of 5-LOX in vivo requires metal 
binding, translocation from the cytosol to the nuclear membrane, protein-complex formation with 
FLAP (a membrane scaffolding protein), and regulation by phosphorylation and additional 
allosteric regulators. 5-LOX is also regulated through autoinactivation.85  
It is hypothesized that the non-turnover dependent autoinactivation mechanism is due to 
oxidative inactivation of the catalytic iron or loss of iron coordination. In vitro incubation of 5-
LOX with reducing agents such as glutathione increases the enzymatic half-life of 5-LOX, 
indicating either reactive oxygen species or hydrogen peroxides could play a role in in vivo 5-LOX 
loss of activity. Autoinactivation of 5-LOX is believed to be important to organism health by 
limiting LT production. However, this native lack of structural stability creates obstacles during in 
vitro studies. The turnover rate for purified wild type (WT) 5-LOX decreases by approximately 
50% when stored at 4 °C for 20 hours.86 Common methods for improving protein stability have 
been tested, such as adjusting buffers to increase viscosity, addition of chelating or reducing 
reagents, and addition of co-factors or analogs. However, these methods did not increase the 
enzymatic half-life. To obtain a crystal structure of 5-LOX, a mutated version of 5-LOX had to be 
created with eight different site mutations. This mutated 5-LOX is called “Stable 5-LOX”. The 
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mutations increased the enzymatic half-life from approximately 7 hours to 16 hours at 37 °C, and 
increased the melting temperature for the enzyme by 3 °C.87  
 
Figure 6. Crystal structure of Stable 5-LOX. The PLAT domain is dark gray while the catalytic 
domain is light gray. Site mutations are represented by spheres, with green representing membrane 
associating amino acids (Δ40-44GS, W13E, F14H, W75G, and L76S), yellow representing the 
cysteines (C240 and C561A), and blue the destabilizing sequence (K663E, K664N, K665L). Key 
helices are also labeled with α-2 in tan, α-7 in pink, α-8 in purple, α-14 in orange, and α-16 in cyan.  
 
Structural analysis of Stable 5-LOX 
Stable 5-LOX is mutated in the proposed membrane-associating amino acids (Δ40-44GS, 
W13E, F14H, W75G, and L76S), and a pair of cysteines (C240A and C561A) that are able to form 
disulfide bonds are mutated to alanines. In addition, a triple lysine sequence (K663-K665) located 
on the turn before the terminal helix was mutated to ENL (E663-L665). The triple lysine sequence 
was identified as a “destabilizing sequence” as it projected K665 towards R651, resulting in 
W13E 
F14H 
W75G 
L76S 
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repulsion between side chains and creating structural strain on the terminal helix. The triple-K 
sequence was mutated to the motif found conserved to other LOX sequences (ENL).  
The crystal structure of Stable 5-LOX at 2.4 angstrom resolution was determined in 2011.88 
There are several features of the structure that are conserved in other LOX crystal structures. The 
catalytic iron is coordinated by 3 histidines (H367, H372, and H550) and the carboxyl group on 
the C-terminus. The active site is structured by four main α-helices (α-helix 7, α-helix 8, α-helix 
14, and α-helix 16). Analysis of other mammalian LOX crystal structures revealed that these 
helices have similar positions and orientations in all LOXs.87 The Stable 5-LOX structure differs 
significantly from the majority of other LOXs by the structure of its α-helix 2. In most LOX crystal 
structures, α-helix 2 consist of 6 to 7 turns where as in 5-LOX and 11R-LOX from Gersemia 
fruticose, the helix consists of 3 turns and two unstructured loops (Figure 7).72 This configuration 
greatly limits accessibility to the active site. Specifically, the positions of F177 and Y181 on α-
helix 2 obstruct access to a hydrophobic channel in the active site. In other LOX structures this 
channel is open and allows substrate entry without structural changes. 5-LOX α-helix 2 has no 
consequential differences when compared to the primary sequences of other LOXs with the 
exception of an alanine (A606 in 5-LOX and A612 in 11R-LOX) and its role in the different helix 
formation remains inconclusive. F177 and Y181 in 5-LOX are conserved in other LOX primary 
sequences, indicating that the blocking of the active site in 5-LOX and 11R-LOX is most likely 
due to α-helix 2 distinctive bent shape and the positioning of the bulky side chains in these LOX 
isozymes. 
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Figure 7. Similarities of LOX crystal structures. (A) Alignment of LOX structures with 5-LOX 
in orange, 8R-LOX in blue, and 15-LOX-2 in gray. (B) Differences in α-2 between conserved 
helices seen in 8R-LOX and 15-LOX-2 and bent helix in 5-LOX.    
 
 The active site of 5-LOX is lined with conserved hydrophobic leucines (L368, L373, L414, 
and L607). These leucines are observed in all AA metabolizing LOXs. The closed cavity has a 
volume of 663 Å3 which allows space for AA binding in several different orientations.87 However, 
the structural changes required for substrate entry into the active site are inconclusive. Currently, 
there are two proposed routes. The first proposal is that the phenylalanine and tyrosine that block 
the channel are removed from the opening through local structure fluctuations that allow substrate 
entry. The second proposal is a rotamer shift in the side chain of W147 that allows AA to complete 
a “back-entry”. Both mechanisms would result in the substrate ending in the proper active site 
regio- and stereo- position. However, the latter model would require significantly fewer 
conformational changes. 
 The PLAT domain of Stable 5-LOX has the putative membrane associating amino acids 
mutated, therefore, limiting structural information on 5-LOX membrane association. Ca2+ is 
known to reversibly bind to the PLAT domain of 5-LOX with a Kd of 6 µM and equilibrium 
Y181 
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α-2 
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dialysis experiments indicate that two Ca2+ bind to a single enzyme molecule. The PLAT domain 
consists of a conserved set of eight β-strands forming a β-barrel-like structure. Structural analysis 
of 5-LOX upon membrane association is currently lacking, however, computational modeling 
predicts that W75 will insert approximately 9 Å into the membrane. Experiments measuring 
fluorescence energy transfer between tryptophans in the 5-LOX PLAT domain and 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-(1-pyreneslfonyl) in lipid vesicles indicate that 5-LOX 
forms a tighter association with the membrane as membrane fluidity increases and in the presence 
of zwitterionic phospholipids.89,90 This corresponds to in vivo studies that demonstrate 5-LOX 
associates to the nuclear membrane, as phosphatidylcholine with AA esterified in the sn2-position 
is the predominant phospholipid in the nuclear membrane.  
 
Allosteric regulation of 5-LOX 
5-LOX enzymatic activity is allosterically regulated by selective phosphorylation and 
binding of adenosine triphosphate (ATP). ATP stimulation of 5-LOX activity was first observed 
when ATP that was added to crude cell lysates of peritoneal PMN leukocytes increased 5-LOX 
activity.91 The allosteric mechanism for ATP modulation of 5-LOX does not involve ATP 
hydrolysis as it is also activated by ADP and AMP.91 The ATP binding effect is only observed 
when Ca2+ is present, indicating the importance of membrane association in ATP allosteric 
regulation. The molecular mechanism of allosteric regulation by ATP is not elucidated despite the 
finding that bound ATP acts to stabilize 5-LOX. 
 5-LOX is also allosterically regulated by phosphorylation. 5-LOX has been reported to 
phosphorylate three different amino acids, S271, S523, and S663. Phosphorylation of 5-LOX was 
first identified in HL60 cells that were ionophore stimulated. When tyrosine kinase inhibitors were 
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added to cell cultures, 5-LOX did not translocate to the membrane efficiently and exhibited 
decreased leukotriene synthesis, demonstrating tyrosine kinase phosphorylated 5-LOX.92 In 
addition, later experiments identified an inhibitor of mitogen-activated protein kinase-activated 
protein kinase (MAPKAP) that prevented 5-LOX translocation and limited leukotriene production 
in fMLP-challenged neutrophils.93 MAPKAP is phosphorylated by p38 mitogen-activated protein 
kinase, which is activated by increased Ca2+ concentrations. This indicates that Ca2+ not only 
promotes 5-LOX activity via membrane association but also promotes 5-LOX phosphorylation by 
MAPKAP. Mutation of S217 to an alanine abolished MAPKAP phosphorylation of 5-LOX and 
reduced LT biosynthesis, demonstrating that MAPKAP phosphorylates S217.94  
Another MAP kinase (MAPK1) phosphorylates 5-LOX in vitro on S663. This 
phosphorylation event increases leukotriene production in PMN leukocytes.95 Phosphorylation at 
S523 by protein kinase A, unlike phosphorylation at S217 and S663, directly suppresses LT 
biosynthesis in vitro and in vivo. S523 phosphorylation also prevents 5-LOX translocation to the 
nuclear membrane.96 It was previously known that cyclic adenosine monophosphate and 
exogenous adenosine inhibited 5-LOX catalytic activity.91 These molecules activate protein kinase 
A providing a connection for their 5-LOX catalytic suppression.  
The phosphorylation of 5-LOX at S663 was further investigated and provided surprising 
results. In vitro experiments showed an increase in HpETE products formed by 5-LOX upon 
phosphorylation by ERK2. However, this data is contradicted by in vivo experiments which 
showed a decrease in leukotriene production in cells with increased ERK2 expression. Stable-5-
LOX was mutated at S663 to aspartic acid to mimic phosphorylation at this site. This mutated 5-
LOX enabled connection of the two observations. S663D-Stable 5-LOX demonstrated robust 15-
HpETE formation in place of 5-HpETE formation. In addition, discrete amounts of LXA4 were 
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also detected. A crystal structure of the S663D mutant was determined with AA bound to the active 
site. Upon AA binding, α-helix 2 and the arched helix that structure the exterior of the active site 
become displaced, resulting in the alignment with the open configuration observed in the crystal 
structure of human 15-LOX-2. The orientation of AA in the active site results in C-13 positioning 
over the catalytic iron for hydrogen abstraction. However, the carbon chain adopts an orientation 
that significantly differs from the orientation observed by the substrate mimic in the crystal 
structure of human 15-LOX-2.97 Therefore, structural changes required for substrate entry and 
substrate binding orientation require further investigation. Current structural data of 5-LOX 
provides putative models for 5-LOX enzymatic and regulatory mechanisms, however, additional 
investigations on substrate binding and protein complex formations will assist in the full 
elucidation of these mechanisms.    
 
15-Lipoxygenase 
 15-LOX has been observed to possession of both pro- and anti-inflammatory properties. In 
mouse models, analogs of LXs, downstream products of 15-LOX oxygenation of AA, were tested 
to investigate the effect on PMN infiltration and vascular permeability. A LXA4 analog was able 
to inhibit PMN migration and tissue biopsies, indicating that the LX analog was able to inhibit 
inflammation as efficiently as the LTB4 receptor antagonist.
98 15-LOX has also been implicated 
to propagate inflammation by increasing the formation of atherosclerotic plaques.99 In addition, 
15-LOX and 15-HpETE have an elevated presence in carotid lesions.100 In mouse models of 
hyperlipidemia and in atherosclerosis-induced mammalian models, increased 15-LOX expression 
results in an increase in low density lipoprotein oxidation.101 An increase in lipid oxidation results 
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in a release of pro-inflammatory mediators and promotes the transformation of macrophages to 
foam cells, an important step in the formation of atherosclerotic plaques.  
 
Figure 8. Crystal structure of 15-LOX-2. (A) Overall structure of 15-LOX-2 with Ca2+ bound 
to the PLAT domain and a substrate mimic, C8E4, bound to the active site. Conserved α-helices 
that define the active site are highlighted by varying colors. (B) α-helices involved in the active 
site are highlighted to clarify substrate binding. (C) Rotation of the active site, reveals an open 
channel that allows substrate to slide into the active site.  
 
15-LOX isoforms and their crystal structures 
In humans, two isoforms of 15-LOX are expressed, 15-LOX-1 and 15-LOX-2. The 
isoforms have a modest degree of sequence similarity (37%), and their substrate specificity and 
cellular distribution are significantly different.102 15-LOX-2 has the highest degree of similarity 
with 5-LOX (42%) and less than 38% similarity with other LOX that have been crystalized. 15-
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LOX is primarily expressed in human (and rabbit) airway epithelial cells, eosinophils, 
reticulocytes, macrophages, and MCs.103 Human 15-LOX-1 mainly synthesizes 15-HpETE with a 
small amount of 12-HpETE. Therefore, this 15-LOX isoform is also called 12/15-LOX.104 Human 
15-LOX-2 solely produces 15-HpETE when oxygenating AA.105  
 
Figure 9. 15-LOX-2 active site. Amino acids that line the active site of 15-LOX-2 with C8E4 
bound. Residues that define the active site shape are in gray with invariant leucines and isoleucines 
in green. A416, which is responsible for directing oxygen direction is in yellow and histidines that 
coordinate the catalytic iron are in blue. 
 
The crystal structures of rabbit 15-LOX-1106 and human 15-LOX-2107 have been 
determined. The 2.4 Å crystal structure for rabbit 15-LOX-1 was the first mammalian LOX to be 
crystallized and the crystal structure had an aryl carboxylate inhibitor bound in the active site. This 
structure was the first to reveal the structural features that are now associated with mammalian 
LOXs. The 2.65 Å structure for human 15-LOX-2 was determined in 2014 by Dr. Marcia 
Newcomer’s lab (Figure 8). The crystal structure displayed the typical LOX fold with an N-
terminal PLAT domain and catalytic domain composed of α-helices.107 The catalytic iron is 
H553 
H373 
H378 
A416 
A188 
F184 
L412 
L374 
E369 
R429 
V426 
V603 
V427 
L610 
I421 
L420 
A606 
 29 
 
positioned by the side chains of conserved histidines (H373, H378, and H553), the main chain 
carboxyl of the C-terminal (I676), and a water molecule. The core of the catalytic domain is 
composed of the same helices that are observed in other crystalized LOXs (α-helix 7, α-helix 8, α-
helix 14, and α-helix 16).  
In the active site of the 15-LOX-2 crystal structure, electron density for a ligand was seen 
to be positioned above the catalytic iron. The most likely identity was a polyoxyethylene detergent, 
tetraethylene glycol monooctyl ether (C8E4), which was added to obtain diffraction-quality 
crystals. C8E4 is bound in a U-shaped conformation (Figure 9). Moreover, AA is superimposed 
over C8E4, carbon-13 is positioned above the catalytic iron for the hydrogen abstraction step in 
the catalytic mechanism. This suggest the orientation and conformation adopted by C8E4 reflects 
those of AA. In addition, C8E4 was identified as a competitive inhibitor for 15-LOX-2.107  
As discussed previously, α-helix 2 has two distinct conformations observed in LOX crystal 
structures. The α-helix 2 in 15-LOX-2 is straight and consists of 6 turns. This allows an opening 
that would permit AA to slide into the active site through interactions with hydrophobic side chains 
(Figure 8). Several amino acids are conserved throughout LOX active sites. Conserved leucines 
and isoleucines are hypothesized to position the substrate in the U-conformation. In 15-LOX-2, 
these amino acids are L374, I412, L420, and L610 (Figure 9). In addition, several hydrophobic 
side chains are believed to grease the active site and allow hydrophobic interactions to stabilize 
the substrate. If AA is positioned to overlay with C8E4 in the active site, R429 would be able to 
stabilize the polar head group of AA. Another conserved amino acid is A416 in 15-LOX-2, which 
is observed in the active site of S-LOXs and has been shown to direct stereo-specificity of the 
molecular oxygen attack on AA (Figure 9).74                                                                                                                                    
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15-LOX-2 membrane association 
In intact mammalian cells, 15-LOX-2 translocates to the plasma membrane where it 
oxygenates AA to initiate eicosanoid synthesis. In addition, 15-LOX-2 is observed to oxygenate 
AA-bearing phospholipids without the need for a lipase or for re-esterification of the product.74 
Membrane association in 15-LOX-2 is Ca2+ dependent and in intact cells is necessary for substrate 
acquisition. The PLAT domain of 15-LOX-2 has two apparent Ca2+ binding sites. This differs from 
other reported structures (11R-LOX and 8R-LOX) which have three binding sites (Figure 10). In 
15-LOX-2, Ca2+ binding site 1 is located at a turn containing amino acids 39-44. The site is 
coordinated by D39 and E44 side chains and main chains from N39 and G42, and the fifth site is 
coordinated by a water molecule (Figure 10).  
The second Ca2+ binding site is stabilized by a hydrophobic loop between P74 and A86. 
This loop is projected approximately 20 Å from the PLAT domain (Figure 10). The loop’s position 
is restrained by a crystal-packing contact, with the loop nestled into the active site entrance of an 
adjacent protein. This loop is composed of a unique sequence when compared to other human 
LOXs as seen by the sequence alignment in Figure 10. Other human LOXs are believed to 
associate to the membrane by conserved hydrophobic amino acids located on one face of the PLAT 
domain. The evolutionary need for an additional hydrophobic loop in 15-LOX-2 is currently not 
well understood. It is hypothesized that this loop may be stabilized in an extended position by Ca2+ 
binding, which allows it to be buried into the membrane to serve as a hydrophobic anchor. In vitro 
assays with nanodiscs used as a membrane mimic indicated that when both Ca2+ binding sites were 
mutated (D39A/E44A/D85A), 15-LOX-2 will not associate to the nanodiscs but does retain its 
enzymatic activity.107  
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Figure 10. Alignments of LOX PLAT domains. PLAT domains of LOXs are aligned to show 
structural differences (green is 8R-LOX, purple is 11R-LOX, and tan is 15S-LOX). These 
alignments highlight amino acids involved in Ca2+ binding. Site 1 is boxed in red, and site 2 in 
green. Amino acids that interact with Ca2+ ions through side chains are in solid lines, while amino 
acids main chains that interact with Ca2+ ions are in dashed lines. The hydrophobic loop that 
protrudes from the PLAT domain in 15-LOX-2 is boxed in blue.  
 
Some LOXs are known to interact with preferred phospholipids upon membrane 
association. 15-LOX-1 primarily targets the plasma membrane in human DCs. In addition, in vitro 
membrane association studies utilizing lipid vesicles with AA that are composed of 
phosphatidylcholine (PC), phosphatidylinositol-4,5-bisphosphate (PI-4,5-BP) and PI-3,4-BP 
increased 15-LOX-1 activity relative to lipid vesicles containing solely zwitterionic 
phospholipids.108 This result agrees with in vitro FRET studies that utilized small unilamellar 
vesicles (SUV) with varying phospholipid content to identify that 11R-LOX prefers association 
with vesicles containing phosphatidylethanolamine and anionic phospholipids.82  
 32 
 
Allosteric regulation of 15-LOX 
LOXs can be allosterically regulated by their enzymatic products. This process was first 
identified in soybean LOX-1 and human 15-LOX-1. A synthetic fatty sulfate, oleyl sulfate, was 
found to increase the kinetic isotope effect in both enzymes and stopped-flowed experiments 
further demonstrated that the allosteric binding site differed from the substrate binding site.109 15-
LOX-2 has been extensively investigated for allosteric regulation by oxygenated fatty acids. These 
studies demonstrated an increase in the enzymatic turnover for AA metabolism from binding of 
13(S)- hydroxy-9Z,11E-octadecadienoic acid (13-HODE). This allosteric effect was not repeated 
for AA oxygenated product 15-HpETE or 12-HpETE, indicating the allosteric site is specific. The 
site was also found to be pH dependent as increased pH correlated with increased allosteric effect. 
In addition, a deletion of the PLAT domain alters the degree of allostery but did not eliminate the 
allosteric effect, indicating that the allosteric ligand binding site is most likely on the catalytic 
domain.110 As this literature review on 15-LOX-2 demonstrates further investigations of the 
structural dynamics involved with 15-LOX-2 enzymatic and allosteric mechanisms, in addition to 
membrane association are needed to fully understand how 15-LOX-2 functions. 
  
5-Lipoxygenase Activating Protein (FLAP) 
 Generation of free AA by the hydrolysis of phospholipids by cPLA2 is not sufficient to 
properly initiate the biosynthesis of LTs in intact cells. 5-LOX activity requires the expression of 
an integral membrane protein for the oxygenation of AA. This protein was identified by Merck-
Frosst while testing newly developed therapeutics for inflammation.111 Compounds MK-886 (from 
Merck) and Bay X1005 (from Bayer) are able to inhibit 5-HpETE synthesis without affecting the 
enzymatic activity of either 5-LOX or cPLA2.
112,113 The mechanism of these pharmaceuticals was 
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unidentified until a photoaffinity labeling analog of MK-886 and a MK-886 affinity gel was used 
to identified an 18 kDa integral membrane protein that was essential for the biosynthesis of LTs 
in intact cells.111 The protein was called FLAP as it was hypothesized to initiate 5-LOX activity 
by acting as a scaffold protein. FLAP appears to have no catalytic activity and its role in LT 
biosynthesis is not fully understood, however, it is shown to directly bind AA.114 
 
Figure 11. The 4.0 resolution crystal structure of FLAP. (A) The FLAP homotrimer with each 
monomer a unique color and the iodinated analog of MK-591 in gray. (B) Rotated (cytosolic) view 
of FLAP crystal structure. FLAP contains a large hydrophobic cavity accessible via an opening at 
the lumen/membrane interface.   
 
 Studies utilizing fluorescence lifetime imaging microscopy (FLIM) demonstrated 5-LOX 
translocates to the nuclear membrane to form a protein complex with FLAP in Ca2+ stimulated 
cells.115 Direct interaction between 5-LOX and FLAP led to the current hypothesis for FLAP’s 
role in LT biosynthesis. FLAP is proposed to be a membrane scaffolding protein that facilitates 
Cytosol 
Lumen 
30 Å 
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the transfer of AA from the membrane to 5-LOX. This hypothesis is supported by the identification 
of FLAP as an AA binding protein through photoaffinity studies.114 In addition, FLIM studies 
indicate that AA binding to FLAP alters the conformation of the protein to promote a tighter 
association between FLAP and 5-LOX.34  
 
Structural analysis of FLAP  
 FLAP is a member of the membrane-associated protein in eicosanoid and glutathione 
metabolism (MAPEG) superfamily. It is the only superfamily member that does not bind 
glutathione or have an identified enzymatic activity. Sequence alignment of superfamily members 
shows FLAP lacks the conserved amino acids that bind glutathione and are present in all other 
MAPEG members. A 4.0 Å crystal structure of FLAP was determined in 2007 with MK-591 
bound, a LT biosynthesis inhibitor (Figure 11).116 FLAP crystallized as a homotrimer with MK-
591 bound in small openings located in the middle of the transmembrane (TM) helices. Each 
monomer of FLAP contains four TM helices with the N- and C-termini located on the luminal end 
and projected into the perinuclear space. The helices are connected by two elongated cytosolic 
loops (CL1 and CL2) and a shorter luminal loop (L1). The unstructured cytosolic surface loops 
connecting α-helix 1 to α-helix 2 (CL1) and α-helix 3 to α-helix 4 (CL2) in FLAP are highly 
conserved in different species, indicating a possible role in protein or ligand binding.  
 The orientation of FLAP helices and loops has a high degree of consistency with LTC4S, 
another member of the MAPEG family for which a structure has been determined.117 LTC4S binds 
LTA4 and glutathione to synthesize LTC4. When the structure of FLAP is compared to another 
family member, microsomal prostaglandin E1 Synthase (MPGES-1), there are significant 
differences in conformation and in the orientation of helices. The MPGES-1 structure contains a 
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small helical domain between α-helix 1 and α-helix 2 that contains the site for glutathione binding 
and the active site.118 The structural differences between MPGES-1 and FLAP explain FLAP’s 
lack of glutathione binding and enzymatic activity. 
 Surface maps of the FLAP homotrimer reveal a flattened cytosolic top and a pointed 
luminal base. Hydrophobic residues line the TM helices to form nonpolar contacts with the 
membrane and the cytosolic end contains positively and negatively charged residues. Several parts 
of the cytosolic end are charged and may be involved in interactions with 5-LOX. There are several 
inter-subunit contacts distributed throughout α-helices 1, 2, and 4 in FLAP monomers. There is 
also an approximately 3200 Å3 hydrophobic pocket in the center of the trimer. This pocket can be 
accessed by a 6 Å entrance opening to the lumen or laterally in through small openings between 
the TM helices. This central cavity extends to the middle of the trimer and is constricted by a bend 
in TM helix-2 due to P65 in FLAP. Proline induced distortions of α-helices can act as a molecular 
hinge and are observed in TM proteins involved in signal transduction and solute transport.119 
Interestingly, while this pocket is mainly hydrophobic, the entrance and ending point are 
negatively charged.  
 The LT biosynthesis inhibitor MK-591 is bound to a small cavity found in the membrane 
spanning region between α-helix 2 and α-helix 4. This may help illuminate an AA transfer 
mechanism. One proposal is that AA may diffuse through the nuclear membrane after 
phospholipid hydrolysis, enter into the hydrophobic cavity of FLAP through the small opening 
between the helices and then eventually diffuse through the luminal cavity out of the membrane 
into the 5-LOX active site for oxygenation. Another model is based on the notion MK-591 can 
inhibit a FLAP conformational change that takes place upon AA binding, which allows the 
substrate to be transferred to the 5-LOX active site.  
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FLAP as a pharmaceutical target  
 FLAP has received significant attention from pharmaceutical companies due to its essential 
role in LT biosynthesis and its limited involvement with other cellular pathways. The most 
prevalent drugs for regulating LT biosynthesis are three Cys-LT receptor antagonists: Zafirlukast, 
Pranlukast, and Montelukast. However, in addition to Cys-LTs, 5-HpETE and LTB4 propagate 
inflammation making FLAP a promising alternative for regulating LT mediated 
inflammation.11,120 The modest resolution of the FLAP crystal structure and inadequate 
information on the FLAP molecular mechanism of AA transfer prevents rational structure based 
drug design. The FLAP inhibitor MK-591 binds to FLAP with high affinity (IC50 of 36 nM) in 
vitro, however, in vivo, low solubility and unspecific interactions of MK-591 leads to lower affinity 
and adverse reactions in the form of skin rashes. Similar limitations were observed for another 
FLAP inhibitor, MK-886.121 However, no drugs have currently passed phase 1 clinical trials. 
Additional information on the mechanism of AA transfer from FLAP and 5-LOX association may 
be beneficial in the development of novel inhibitors.     
    
Hydrogen/deuterium exchange mass spectrometry 
 The elucidation of the function of a protein on a molecular level can be assisted by 
determining the three-dimensional structure of the protein. Commonly used techniques in 
structural biology are nuclear magnetic resonance (NMR) spectroscopy and X-ray 
crystallography.122 Both methods provide vital information on protein-ligand interaction and 
protein-protein interactions. However, both are compromised by obstacles that limit their practical 
utility. X-ray crystallography requires collection of structural data using non-native solid-state 
samples and provide little insight into native protein motions. Crystal packing may also alter the 
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native conformational state. In addition, proteins with high intrinsic disorder will not readily form 
well-diffracting crystals. On the other hand structure determination by NMR spectroscopy can be 
completed at ambient temperatures in solution. This technique can also provide information on 
structural dynamics. However, this technique requires high concentrations of protein and is limited 
to smaller proteins (usually less than 150 amino acids).123 Backbone amide hydrogen/deuterium 
(H/D) exchange mass spectrometry (MS) provides a complementary method to X-ray 
crystallography and NMR spectroscopy to investigate protein structure and conformational 
dynamics.  
        
Figure 12. The Linderstrøm-Lang model of H/D exchange. Amide protons that are solvent 
exposed exchange with deuterons in the solvent within milliseconds. Amide protons that are buried 
within the protein or involved in hydrogen bonding exchange only when structural fluctuations (ko 
and kc) allow solvent exposure, which may span any length of time between seconds and years. 
This allows analysis of observed exchange kinetics to provide insight into structural dynamics and 
protein conformations. 
 
 
H/D exchange theory 
 H/D exchange was first described in the 1950s by Kaj Ulrik Linderstrøm-Lang when the 
extent of deuterium incorporation on insulin solubilized in D2O was calculated via density gradient 
ultracentrifugation.124 The first experiment of H/D exchange MS was completed with horse 
cytochrome c incubated in D2O at varying time points, then proteolyzed by pepsin, and analyzed 
using fast atom bombardment MS.125 The advent of electrospray ionization (ESI) and matrix-
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assisted laser desorption/ionization (MALDI) in the 1980s allowed H/D exchange analysis of 
intact proteins. Coupling of protein digest with liquid chromatography (LC) to separate generated 
peptides and ESI ionization to obtain H/D exchange data at a peptide resolution of a whole, intact 
protein was first completed with apo- and holo-myoglobin in 1994.126  
                 
 
Figure 13. H/D exchange-MS experimental method. (A) “In-exchange” and “back-exchange” 
of deuterium during the D2O incubation and quenching steps of H/D exchange is depicted (B) The 
conditions used for D2O incubation and the quenching/ protein digestion steps in H/D exchange 
MS are shown. (C) Increases in m/z of isotopic envelopes are measured for each peptide to 
calculate the average mass. (D) Plotting the number of deuterons verse time for each peptide in 
different protein states allows for a comparison of exchange kinetics for individual peptides that 
reports on the final state of the intact protein. 
 
 Hydrogen exchange is both acid- and base-catalyzed. At physiological pH, which is used 
in the majority of H/D exchange studies involving intact proteins, the hydrogen exchange is 
primarily base-catalyzed. In a base-catalyzed hydrogen exchange, the hydrogen is abstracted from 
the amide nitrogen by a hydroxide ion and protonated by a solvent hydrogen. The intrinsic rate of 
A B C D 
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hydrogen exchange is effected by various conditions such as pH, adjacent amino acids, solvent 
exposure, and chemical interactions.127 The rate of backbone amide hydrogen exchange is 
primarily dependent upon the rate of structure unfolding (ko) and refolding (kc), which is mediated 
by local structural dynamics that disrupt the hydrogen bonds and results in temporary solvent 
access (Figure 12).123 Therefore, protein conformation and conformational changes between 
different states of a protein can be identified by measuring the rate of deuterium incorporation as 
a function of time.       
 
H/D exchange methodology  
 H/D exchange occurs at ambient temperature and at a neutral pH, with continuous labeling 
being the most common analysis technique. In this method purified protein, in an aqueous buffer, 
is diluted with deuterated solvent and incubated at approximately 25 °C and neutral pH. The 
incubation time ranges from 15 seconds to hours or days. This is identified as the “in-exchange” 
process. The “in-exchange” is quenched by lowering the pH to 2.3 and the temperature to 0 °C by 
the addition of quenching buffer that has been cooled in an ice-bath (usually an acidic aqueous 
buffer). This quenching reduces hydrogen exchange of backbone amides by several magnitudes, 
but hydrogens on the amino acid’s side chain will “back-exchange” for hydrogen in the quenching 
buffer. Therefore, deuterium incorporated in H/D exchange experiments during the D2O 
incubation is trapped on the amides on the peptide backbone only (Figures 13A and 13B). 
 The sample is then digested by an acidic protease and analyzed by MS. Peptide resolution 
is achieved by coupling reverse-phase LC with ESI-MS in positive mode. The mass to charge ratio 
(m/z) for desired time points is analyzed for the individual peptides. Peptides are identified prior 
to H/D exchange experiments by tandem mass spectrometry (MS/MS). The number of deuterons 
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incorporated on the backbone is calculated for each time point using the centroid of the individual 
peptide isotopic envelope (Figure 13C). The number of deuterons incorporated into the peptide 
back-bone can be plotted as a function of time and fit to a sum of first-order exponential rate terms 
(Figure 13D). The determined kinetic rates are classified as fast, intermediate, and slow. This data 
can provide information on peptide solvent exposure, hydrogen bonding, or local structural 
fluctuations. Changes in the exchange rates between different protein states (e.g. apo protein verses 
ligand bound) indicate alterations in hydrogen bonding due to ligand interaction or conformational 
changes that alter solvent exposure.  
 
Purpose of these studies 
 Historically, inflammation was considered to be most closely associated with pathogenesis 
in autoimmune and chronic inflammatory diseases. However, current research has shown 
increasing connections between inflammation and a variety of other diseases such as several 
cardiovascular diseases, forms of cancer, and even Alzheimer’s disease.4 An extraordinary effort 
has been dedicated to the studies of inflammatory mediating molecules and the enzymes that 
synthesize them. LOXs are known to play a role in the initiation and resolution of inflammation 
through signaling pathways associated with their enzymatic products.11 While 70 years of LOX 
research has developed a strong knowledge base on the superfamily, ongoing investigations on 
LOX protein structure, biological functions, and cellular regulation will continue to extend our 
understanding of inflammation.   
 Of particular interest, the regulation of LOX activity has been identified as a key area for 
pharmaceutical development.2 Historically, drug discovery frequently began with identification of 
a lead compound. In this approach, the lead compound is identified either by characterizing a 
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natural ligand of the protein or by completing in vitro assays involving screening of compounds 
from libraries. The lead compound is then systematically modified and tested for biological 
activity to extract structure-activity relationships between the protein and drug. Currently, high 
through-put screening leverages automation to assay the impact of a large number of drug-like 
compounds on a biological or biochemical activity associated with the target protein.128 High 
through-put screening allows researchers to quickly test and detect possible protein-drug 
interactions. This approach is extensively used today.129 However, high through-put methods are 
often limited by their cost and oversimplification of cell-drug interactions. 
 Another method for drug discovery is structure-based drug design, or rational drug design, 
which has been used since the late 1980s. This method begins by identifying a target protein 
involved in disease pathogenesis or critical cellular functions. The target protein undergoes 
structural analysis most commonly through crystallography or NMR methods. The protein binding 
site is revealed by analysis of the structural data combined with methods such as protein 
mutagenesis, binding assays, and reaction kinetic assays. Structural information regarding the 
protein-ligand complex is used to rationally modify the ligand to produce novel analogs that are 
more potent or specific for the protein active site.  
 Due to the limited number of pharmaceuticals on the market that target proteins involved 
in LT, and LX biosynthesis, further research focusing on the structural analysis of these proteins 
can be expected to provide essential information for the development of novel drugs through 
structure-based drug design techniques. While the available structures for human FLAP, 15-LOX-
2, and Stable 5-LOX are indispensable, they provide only a static structural depiction of protein 
conformation.107,87,116 In addition, technical difficulties involved in obtaining LOX or FLAP 
crystal structures limit the ease of obtaining structures that include bound substrates or inhibitors. 
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The aim of this dissertation is to elucidate the role of structural dynamics and conformations in the 
LOX catalytic and regulatory mechanisms. Backbone amide H/D exchange MS was employed as 
a route to complement the current structural information on these proteins.  
      
Figure 14. 15-LOX-2 reaction in intact cells. Ca2+ concentrations are increased in the cell in 
response to stress. Ca2+ ions bind to the PLAT domain of 15-LOX-2, resulting in a translocation 
from the cytosol to the membrane. 15-LOX-2 then binds its substrate, AA, and oxygenates it to 
form 15-HpETE. 15-HpETE is further metabolized by downstream enzymes to form LXs, which 
initiate the resolution of inflammation.  
 
 This study focuses on the 15-LOX-2 reaction mechanism in intact cells, in which 15-LOX-
2 binds Ca2+ ions to the PLAT domain, promoting translocation to the cellular membrane for 
acquisition of substrate (Figure 14). The crystal structure suggests that changes in PLAT 
conformation may promote this translocation. However, the work presented in this dissertation 
suggests an alternative model in which binding of Ca2+ changes the electrostatic potential of the 
PLAT domain to promote interaction with the negativity charged head group of phosphatidylserine 
(PS). This work also supports the hypothesis of inter-domain communication playing a role in 
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LOX catalytic activity by identifying changes in structural dynamics in the PLAT domain upon 
AA binding in 15-LOX-2. The observed structural dynamics offer an explanation for 15-LOX-2 
ability to oxygenate substrates with bulky head groups and also suggests a structural mechanism 
for 13-HODE positive allostery in 15-LOX-2. In the cases of 5-LOX and FLAP, our results provide 
a basis for future studies. However, experimental limitations prevented the ultimate goal of 
identifying the FLAP and 5-LOX interaction site. Nevertheless, the limited H/D exchange data 
obtained did provide interesting information on the effects of AA binding to the FLAP homotrimer. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
Buffer salts and common chemicals were purchased in high quality forms from commercial 
vendors. Fatty acids and their oxygenated derivatives including, AA, 15-HpETE, and 13-HODE, 
were purchased from Cayman Chemical Company, Ann Arbor, MI. Phospholipids, such as PS and 
PC, were purchased from Avanti Polar Lipids, Alabaster, AL. Competent cells used in 
transformations were obtained from Merck Millipore, Billerica, MA. PIP and Sphingo-Strips were 
ordered from Thermo Fisher Scientific. 15-LOX-2 and MSP1e3d1 expression plasmids were 
generous gifts from Dr. Marcia Newcomer, Department of Biological Sciences, Louisiana State 
University.  
Methods 
Expression of LOX 
The expression methods for 15-LOX-2 and 5-LOX were adapted from protocols developed 
by Dr. Marcia Newcomer’s lab.107,87 The Stable 5-LOX gene with N-terminal hexa-histidine tag 
was subcloned into pET-14b vector. 15-LOX-2 was subcloned into the pET-Duet-1 vector with a 
N-terminal hexa-histidine tag and co-expressed with E. coli YjgD protein. Rosetta-2(DE3) E. coli 
competent cells were transformed with the LOX expression vectors and grown in 5 mL of Luria-
Bertani (LB) broth with the appropriate antibiotic (100 µg/mL of ampillicin for 5-LOX and 30 
µg/mL kanamycin for 15-LOX-2) for approximately 14 hours. The LB cultures were then diluted 
(1:200 dilution for 15-LOX-2 and 1:100 dilution for 5-LOX) with Terrific Broth (TB) 
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supplemented with 0.4% glycerol and antibiotic (100 µg/mL of ampillicin for 5-LOX and 30 
µg/mL of kanamycin for 15-LOX-2). The cells were grown in 2 L Erlenmeyer flasks at 37 °C. The 
cultures were incubated at 200 rpm until an OD600 of between 1.0 and 1.2 was reached. The 
temperature was then dropped to 18 °C and the shaker decreased to 160 rpm for leaky protein 
expression. The cultures were grown between 18-24 hours. The cells were harvested by 
centrifugation at 6500 x g and 4 °C for 10 minutes. The resulting cell pellets were stored at -80 °C 
until they were used in later experiments. 
 
Purification of 5-LOX 
Frozen cell pellets were resuspended in Bugbuster 10x protein extraction reagent 
(Novagen) with 2 mL of solution per 1 gram of cell pellet. In addition, 60 µg/mL of lysozyme, and 
2 Complete Mini Protease Cocktail Inhibitor tablets (Sigma Aldrich) were added to the 
resuspension solution. Resuspended cells were stirred at 4 °C for approximately 30 minutes to 
promote cell lysis. Cells were further lysed by sonication on ice with 1 second pulses (50% power, 
60% duty cycle, and 2 min on, 3 min off). Cellular debris was cleared by centrifugation at 30,000 
x g for 30 minutes at 4 °C. The cleared lysate was incubated with 10 mL of Ni2+-NTA agarose 
resin (approximately 5 mL per 25 g of cell pellet) that was pre-equilibrated with 10 x resin volume 
of column buffer (20 mM Tris, 500 mM NaCl, 20 mM imidazole, pH 7.6). The resin-lysate slurry 
was then applied to a gravity column and washed with column buffer containing 35 mM imidazole 
to elute impurities. 5-LOX was eluted with column buffer containing 200 mM imidazole and then 
concentrated to 2 mL using Amicon centrifugal filters (MilliporeSigma) with a molecular weight 
cut off (MWCO) of 30 kDa. Concentrated 5-LOX was dialyzed using Slide-A-Lyzer dialysis 
cassettes (Thermo Fisher Scientific) against 500 mL of sample buffer (20 mM Tris, 150 mM KCl, 
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5 mM TCEP, pH 7.5). 5-LOX was then applied to a HiLoad 16/60 Superdex 200 pg column with 
bed dimensions of 16 x 600 mm, equilibrated with sample buffer.  Fractions (3 mL) were collected 
as the column was eluted with sample buffer. Fractions were analyzed for protein identification 
and extent of purification by SDS-PAGE and western blotting techniques. 5-LOX eluted from the 
column between 70-80 mL. Fractions containing isolated 5-LOX were concentrated using Amicon 
centrifugal filters. The protein was either tested for enzymatic activity or frozen at -20 °C for 
further use. Enzymatic activity of 5-LOX was monitored after thawing of the protein and before 
all H/D exchange experiments. 
 
Purification of 15-LOX-2 
  Cell pellets with overexpressed 15-LOX-2 were lysed in B-PER Bacterial Protein 
Extraction buffer (Thermo Fisher Scientific) (2 mL solution per 1 gram cell pellet). The buffer was 
supplemented with 200 µL of DNase 1 (Sigma Aldrich) and 10 µL per 1 mL lysis solution of 
Problock 2D protease inhibitor cocktail (Gold Biotechnology). Cells were lysed by stirring in 
extraction buffer for approximately 30 minutes at 4 °C followed by probe sonication (1 second 
pulse, 2 minutes on, 3 minutes off) on ice, until no longer viscous. Cellular debris was cleared by 
centrifugation (approximately 17,500 x g) for 30 minutes at 4 °C. Imidazole was added to the 
supernatant to a final concentration of 10 mM. Supernatant was incubated for 30 minutes at 4 °C 
with approximately 10 mL of Co2+-NTA resin (Thermo Fisher Scientific) equilibrated with column 
buffer (50 mM Tris, 500 mM KCl, 10 mM imidazole, pH 8.0). Resin was applied to a gravity 
column and washed with column buffer containing 20 mM imidazole (10 x resin volume). 15-
LOX-2 was eluted with column buffer containing 200 mM imidazole (3 x resin volume) and then 
concentrated to approximately 2 mL using Amicon centrifugal filters with a MWCO of 30 kDa. 
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15-LOX-2 was then applied to a HiLoad 16/60 Superdex 200 pg column with bed dimensions of 
16 x 600 mm equilibrated with sample buffer.  Fractions (3 mL) were collected as the column was 
eluted with sample buffer. Fractions were analyzed for protein identification and extent of 
purification by SDS-PAGE and western blotting techniques. 15-LOX-2 eluted from the column 
between 70-80 mL. Fractions containing isolated 15-LOX-2 were concentrated using Amicon 
centrifugal filter with MWCO of 30 kDa. The protein was either tested for enzymatic activity or 
frozen at -20 °C for further use. Enzymatic activity of 15-LOX-2 was monitored after thawing of 
the protein and before all H/D exchange experiments.  
 
Expression of 5-lipoxygenase activating protein 
The human FLAP gene with a C-terminal hexa-histidine tag was subcloned into a pET-21b 
vector. C43(DE3) competent cells (Lucigen) were transformed with the expression vector and 
grown in 7 mL of LB media between 14-18 hours. The small cultures were diluted 200-fold with 
minimal media (20 mM Na2HPO4, 20 mM KHPO4, 90 mM NaCl, 200 mM NH4Cl, 130 µM CaCl2, 
1 mM MgSO4, 0.4% glucose, 0.3% casamino acids) and grown at 37 °C and 250 rpm until an 
OD600 of 0.4 was reached. FLAP expression was induced by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The cells were cultured further at 
18 °C and 200 rpm for 20 to 24 hours. Cells were harvested by centrifugation at 6,500 x g for 10 
minutes at 4 °C and stored at -80 °C.  
 
Purification of 5-lipoxygenase activating protein 
Frozen cell pellets were resuspended in cold lysis buffer (50 mM KH2PO4, 300 mM KCl, 
1 mM DTT, 1 MM EDTA, 10% glycerol, pH 8.0). Lysozyme was added at 0.2 mg per mL of lysis 
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buffer and stirred for 2 hours at 4 °C. Cells were lysed further by sonication (60% power, 50% 
duty cycle, 2 minutes on, 3 minutes off, 1 second pulses) on ice, until no longer viscous. Cellular 
debris was removed by centrifugation at 10,000 x g at 4 °C for 30 minutes. Then the membrane 
fraction was collected from the supernatant using ultracentrifugation at 100,000 x g for 2 hours 
and 4 °C. The membrane pellets were washed with 50 mM Tris, pH 8.0 and resuspended in cold 
extraction buffer (50 mM KH2PO4, 300 mM KCl, 10% glycerol, 10 mM imidazole, 0.5% dodecyl-
β-maltoside (DDM), pH 8.0). The membrane pellet was solubilized by stirring at 4 °C for 
approximately 18 hours. The membrane extract was then added to 10 mL of Ni2+-NTA agarose 
resin that was pre-equilibrated with 10 x resin volume of the extraction buffer. The membrane 
extract and resin were incubated for 1 hour at 4 °C with gentle mixing. Resin was applied to a 
gravity column and washed with the extraction buffer containing 35 mM imidazole. FLAP was 
eluted from the resin with 3 x resin volume of 50 mM KH2PO4, 300 mM KCL, 10 glycerol, 0.2% 
DDM, 200 mM imidazole, pH 8.0. FLAP was concentrated to approximately 2 mL using Amicon 
centrifugal filters with a MWCO of 10 kDa and dialyzed in sample buffer (20 mM Tris, 300 mM 
KCl, 2.5% glycerol, 1 mM DDT, 0.1% DDM, pH 7.5). FLAP was applied to a HiLoad 16/60 
Superdex 200 pg column (GE Healthcare) equilibrated with sample buffer. The 2 mL fractions 
were tested for protein identity and purification extent by SDS-PAGE and western blotting. Protein 
eluted from the column, using the sample buffer, between 40-50 mL. Fractions containing FLAP 
were concentrated using Amicon centrifugal filters (MWCO of 10 kDa). The protein was frozen 
at -20 °C for further use. Solubility trials using DDM (from 0.01% to 0.2% w/v) and 3-((3-
cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS) (from 0.5-1% w/v) 
were completed to determine buffer conditions that prevented protein aggregation.  
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LOX Activity Assay 
The oxygenation of AA by LOXs can be monitored by measuring the increase in 
absorbance at 238 nm, which arises from the conjugated double bonds found in the LOX reaction 
product HpETE. Stable 5-LOX and 15-LOX-2 enzymatic activities were assayed by measuring 
the product formation with a Perkin Elmer Lambda 45 UV/VIS Spectrometer at 25 °C. Enzymes 
were incubated at 25 °C in 20 mM Tris, 150 mM KCl, pH 7.8 (in addition to 5 mM TCEP for 
Stable 5-LOX).  Assays were performed in activity assay buffer (20 mM Tris, 150 mM KCl, 0.5 
mM CaCl2, pH 7.8). LOXs were added to activity assay buffer to a final concentration between 
0.5 µM and 1 µM. The reaction was initiated by the addition of AA between 80 µM-160 µM (from 
28 mM AA in 100% ethanol stock solution) at 25 °C. The assay components were added so that 
the total assay volume was 1 mL in a quartz cuvette. Absorbance at 238 nm was recorded. Non-
enzymatic oxygenation of AA was also measured under the same conditions to ensure increases 
in absorbance were produced from LOX enzymatic activity. Specific activity was calculated using 
the following equations, where Ԑ is the molar absorbtivity (27,000 L·mol-1·cm-1 for HpETE), b is 
the path length (1 cm), and c is the concentration of HpETE.  
Equation 1.   Absorbance(at 238 nm)  = Ԑ · b · c 
Equation 2.  Specific Activity =  
mg of product
µmol of enzyme ·minutes
 
The specific activity for 15-LOX-2 was similar to the published activity, however, the 
specific activity for 5-LOX was significantly less than reported.107,88 One experimental attempt to 
increase 5-LOX specific activity consisted of adding oxygenated product to the assay, as these 
lipids have been shown to increase 5-LOX activity by oxidizing the catalytic iron in previous 
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studies.130 In this experiment either 10 µM of 13-HpODE or 10 µM of 15-HpETE was added to 
the activity assay (5 µL of 2 mM stock solution in 100% ethanol). The assay had a total volume of 
1 mL and used 1 µM of Stable 5-LOX. 13-HODE or 15-HpETE was added to the protein 
approximately 5 minutes before the reaction initiation. The reaction was initiated by the addition 
of 160 µM of AA (as previously described). The absorbance at 238 nm was monitored for 4 
minutes at 25 °C. 
 
LOX Product Assay 
To identify the regio-specific HpETE being synthesized by 15-LOX-2 and 5-LOX, the 
products were extracted from the activity assays previously described. The activity assay was 
quenched after approximately 10 minutes by acidifying the reaction buffer to pH 4.0 with 5 µL of 
6N HCl. Then 1 x reaction volume of dichloromethane was added to the assay and the mixture 
was shaken vigorously. The organic and aqueous phases were allowed time to fully separate and 
the lower organic layer was extracted. The organic layer was washed with 1 mL of water twice to 
remove remaining acid, salts, and enzyme. A stream of nitrogen was used to evaporate the 
dichloromethane and the remaining product was dissolved in a small volume of 1:1 
methanol/water. Reverse-phase HPLC was performed on the products using a Varian ProStar 
HPLC system with a Kinetex 5µ C18 100A column (30 x 2.1 mm) (Phenomenex) using a mobile 
phase of acetonitrile/water/formic acid (70:30:0.4, v/v/v) at a flow rate of 0.5 mL/min. Elution 
times of the products were observed by monitoring the absorbance at 238 nm and then were 
compared to elution times determined for a HETE standard mixture containing 15-, 12-, 11-, 9-, 
and 5-HETE.   
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Expression and Purification of Membrane Scaffolding Protein 1E3D1 
The membrane scaffolding protein (MSP) 1E3D1 gene in a pET-28 vector was provided 
by Dr. Marcia Newcomer’s lab. pMSP1E3D1 was transformed into Rosetta 2 (DE3) competent 
cells and grown in 5 mL LB cultures for 14-18 hours. The small cultures were added to 1 L of TB 
with 30 µg/mL kanamycin. MSP1E3D1 protein expression was induced with 1 mM IPTG when 
OD600 of 1.0 was reached. The cells were grown for an additional 4 hours at 37 °C. Cells were 
harvested by centrifugation at 6,500 rpm for 10 minutes and frozen at -80 °C.  
Frozen cell pellets were resuspended in lysis buffer with 5 mL per 1 gram cell pellet (50 
mM Tris, 300 mM NaCl, 1% Triton X-100, pH 8.0) supplemented with 2 Complete Mini Protease 
Cocktail Inhibitor tablets and 200 µL of 10 mg/mL DNaseI. Lysozyme (0.2 mg/mL) was added to 
the cell lysate and stirred at 4 °C for 1.5 hours. The cells were further lysed by sonication (60% 
power, 50% duty cycles, 1 sec pulses, 2 min on, 3 min off) on ice. Cellular debris was cleared from 
the lysate by centrifugation at 10,000 x g for 30 minutes and the resulting supernatant was applied 
to 15 mL of Ni2+-NTA agarose resin that was equilibrated with 50 mM Tris, 300 mM NaCl, pH 
8.0. Resin was applied to a gravity column and washed with 10 x resin volume of equilibration 
buffer. Resin was further washed with 10 x resin volume of equilibration buffer containing 50 mM 
imidazole. MSP1E3D1 was eluted from the resin with 5 x resin volume of equilibration buffer 
with 250 mM imidazole. MSP1E3D1 was concentrated to approximately 10 mL using Amicon 
centrifugal filters with MWCO of 10 kDa and dialyzed against 1 L of nanodisc buffer (20 mM 
Tris, 150 mM KCl, pH 8.0).  
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Nanodiscs Preparation  
Nanodiscs formation was initiated by the addition of 100 mM cholate to MSP1E3D1 stock 
(at 6.5 mg/mL) in nanodisc buffer. A 3:1 powder mixture phosphatidylcholine (PC) and 
phosphatidylserine (PS) was added to the solution at a 160:1 lipid:MSP1E3D1 molar ratio. The 
solution was shaken for 1 hour at 4 °C until all phospholipids and cholate were solubilized. 
Nanodiscs buffer was added until cholate concentration was lowered to 25 mM. To remove the 
cholate nanodisc buffer-washed Biobeads (Bio-Rad) were then added to a 0.1 g/mL, and the 
solution was shaken for 1 hour at 4 °C. The mixture was shaken at 4 °C for 2 hours, followed by 
addition of more (0.2 g/mL) Biobeads. The shaking of the mixture continued at 4 °C for another 4 
hours and yet another 0.2 g/mL of Biobeads were added. The mixture was shaken at 4 °C for an 
additional 4 hours and then filtered to remove Biobeads. The spontaneous formation of nanodiscs 
was verified by SECC using a Superose-12 column connected to UV-detector monitoring at 280 
nm. The column was eluted with nanodisc buffer containing 0.5 mM CaCl2. Fractions (1 mL) were 
collected and analyzed by SDS-PAGE, and subsequent western-blotting. 
 The complex of 15-LOX-2 associated with nanodiscs was prepared by, first, estimating the 
nanodisc concentration by measuring the band volumes of MSP1E3D1 from the nanodiscs sample 
and MSP1E3D1 stock standards on an SDS-PAGE gel. 15-LOX-2 concentration was determined 
by UV-vis absorbance at 280 nm. 15-LOX-2 that had been dialyzed in nanodisc buffer was added 
to nanodisc stock and association was promoted by the addition of 0.5 mM CaCl2. Different ratios 
of 15-LOX-2 molecules and nanodiscs were tested with 4 nanodiscs for each 15-LOX-2 molecule 
used in the majority of nanodiscs studies in this work. 15-LOX-2 was incubated with nanodiscs in 
20 mM Tris, 150 mM NaCl, and 0.5 mM CaCl2 for 1 hour at 4 °C and then concentrated to 0.5 mL 
using Amicon centrifugal filters with a MWCO of 30 kDa. 15-LOX-2 association was confirmed 
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by SEC using Superose-12 column (GE Healthcare) that was equilibrated with nanodisc buffer. 
Fractions (1 mL) collected from the observed peaks were analyzed with SDS-PAGE gels and 
western blots to confirm that 15-LOX-2 was associated with the nanodiscs.  
 
PIP and SphingoStrips 
PIP and Sphingo Strips were used to identify the phospholipid that 15-LOX-2 prefers for 
membrane association. The strips were used according to the manufacturer’s instructions. Briefly, 
the membranes were blocked with 3% bovine-serum albumin (BSA) in TBS-T buffer (20 mM 
Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 8.0) and gently rocked for 1 hour at approximately 
25 °C. Then the membranes were incubated with 1 µg/mL of 15-LOX-2 in TBS-T buffer with 3% 
BSA and 0.5 mM CaCl2 for 2 hours at approximately 25 °C. The membranes were rinsed 
thoroughly three times by gently rocking in TBS-T buffer for 10 minutes, followed by incubation 
with a monoclonal mouse anti-penta-histidine antibody (1:3000 dilution) in TBS-T buffer 
containing 3% BSA for 2 hours. The membranes were rinsed four times with TBS-T as described 
before and incubated with an AP-conjugated anti-mouse secondary antibody (1:10,000 dilution) 
in TBS-T buffer containing 3% BSA for 2 hours. The membranes were washed four times with 
TBS-T buffer by gentle rocking for 10 minutes. Protein binding was visualized by incubating the 
strips in alkaline phosphatase staining solution for approximately 20 minutes.  
 
Peptide Mapping by MS/MS 
Prior to H/D exchange MS analyses, all of the proteins analyzed in this work (5-LOX, 15-
LOX, and FLAP) were peptide mapped by LC-MS/MS. The proteins were brought to a 
concentration of 5 µM (5 µL from 50 µM protein stock solution) in cold H2O to a final volume of 
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50 µL. Then 50 µL of quenching buffer was added to the sample. For Stable 5-LOX and 15-LOX-
2 the quenching buffer was 100 mM KH2PO4, 10 mM TCEP, pH 2.4 and for FLAP the quenching 
buffer was 100 mM KH2PO4, 10 mM TCEP, 4 M urea, pH 2.4. Protein digestion was initiated 
with the addition of an acidic protease. Digestion was performed on ice, with pepsin in H2O 
providing the highest sequence coverage for all proteins. 15-LOX-2 optimal digestion was 
completed by addition of 2 µL of 20 mg/mL of pepsin (final sample concentration of 0.4 mg/mL) 
and incubating for 7 minutes. FLAP digestion underwent digestion trials and optimal digestion 
was found when 2 µL of 10 mg/mL pepsin (final sample concentration of 0.2 mg/mL) was added 
and incubated for 7 minutes. 5-LOX optimal digestion was performed with 2 µL of 10 mg/mL 
pepsin (final sample concentration of 0.2 mg/mL) and a 9 minute digestion time. The resulting 
peptides were separated by reverse-phase HPLC utilizing an Aeris PEPTIDE 3.6 µ XB-C18 
column (50 x 2.6 mm, Phenomenex) on ice and connected to ThermoFinnigan LTQ Linear Ion 
Trap with an ESI ionization source set in positive mode. Peptides were eluted with a flow rate of 
0.1 mL/min with a 30 minute gradient (5-50% acetonitrile/H2O containing 0.4% formic acid for 
15-LOX-2 and 5-LOX and 5-75% acetonitrile/H2O containing 0.4% formic acid for FLAP). A 
column washing step was added after each sample (95% acetonitrile/H2O with 0.4% formic acid 
at 0.1 mL/min for 10 minutes). An additional washing step was added to samples containing 
detergents, phospholipids, or fatty acids (50:40:10 propan-2-ol/acetonitrile/H2O containing 0.4% 
formic acid at 0.1 mL/min for 10 minutes). Scans of m/z from 300 to 2000 were utilized for peptide 
detection.  
Peptides were sequenced by data-dependent tandem MS/MS by CID. Collison voltage was 
set to 15V, 25V, and 35V. The putative identity of each peptide was determined by the computation 
program PEAKS Client 6 (Bioinformatics Solutions Inc.). This program determines the identity 
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of the peptide from the experimental parent mass and the raw fragmentation data. PEAKS creates 
theoretical peptide fragmentation patterns based on the type of protease used, the FASTA sequence 
for the protein, MS instrument used, and the parameters for MS. Experimental fragmentation is 
matched with the theoretical fragmentation and a false discovery rate (FDR) is calculated for the 
match. The FDR is calculated using matches for decoy sequences and is reported as a -10log (p) 
value, where p is the probability of a false identification. All peptides with a -10log (p) value 
greater than 20 (equal to a p value of 0.01) were selected and further verified. MassXpert MS 
analysis software presents all possible peptides in the protein with the same parent mass as the 
experimental parent mass. Then the theoretical fragmentation of the peptide is generated by 
ProteinProspector program MS-product and compared to the experimental data. Verified peptides 
are combined to create the peptide coverage map.  
 
Sample Preparation of 15-LOX-2 for H/D Exchange Ligand Binding Experiments 
Several kinetic analyses of backbone amide H/D exchange were performed on 15-LOX-2. 
All samples contained 5 µL of 50 µM 15-LOX-2 in sample buffer (20 mM Tris, 150 mM KCl, pH 
7.8) or sample buffer supplemented with ligands and metals. The metals and ligands were added 
to the sample through the following methods. Purified 15-LOX-2 in sample buffer is called native 
15-LOX-2. In this state, the 15-LOX-2 catalytic iron is coordinated in the active site, but Ca2+ is 
removed by chelation with 5 mM EGTA or EDTA. Samples with EGTA or EDTA were dialyzed 
in sample buffer containing 5 mM of the chelating agent at 4 °C for 20-28 hours. Samples 
containing Ca2+ had 0.5 mM CaCl2 (2 µL of 12.5 mM CaCl2 in H2O) added to the protein stock 2 
minutes before D2O incubation in H/D exchange experiments. 13-HODE, 15-HpETE, and AA 
were added from 100% ethanol to the protein stock 30 seconds before D2O incubation. 
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Complication of data interpretation due to ethanol affecting 15-LOX-2 structure was avoided by 
varying the concentrations of the ligand stock solutions so only 1 µL of ligand was added to the 
samples to achieve the desired concentrations. The sample concentrations of ligands tested ranged 
from 10 µM to 500 µM. 
 
Sample Preparation of 15-LOX-2 for H/D Exchange Membrane Association Experiments 
For analyzing 15-LOX-2 membrane association four different conditions were tested. 
Native 15-LOX-2 and Ca2+ bound 15-LOX-2 samples for H/D exchange were prepared as 
previously described. 15-LOX-2 that was associated to nanodiscs or DDM (at concentrations 
ranging from 0.02% to 0.2%) in the presence of 0.5 mM CaCl2 was also tested. 15-LOX-2 
associated to nanodiscs was prepared as described in the Nanodiscs Preparation section. 15-LOX-
2 associated with DDM micelles was prepared by adding DDM to the desired concentration 
(between 0.02%-0.2% w/v) to the Co2+-NTA resin elution buffer as described in the 15-LOX-2 
purification section. In the 15-LOX-2-DDM complex samples, CaCl2 was added (to a final sample 
concentration of 0.5 mM) 2 minutes before D2O incubation. 
   
FLAP Sample Preparation for Hydrogen/Deuterium Exchange 
FLAP stored in sample buffer (20 mM Tris, 300 mM KCL, 2.5% glycerol, 1 mM DDT, 
0.02% DDM, pH 7.8) was used in H/D exchange experiments. To investigate ligand binding H/D 
exchange experiments were conducted on native FLAP unbound to any ligands and compared to 
FLAP with bound AA and FLAP with bound MK-886. FLAP samples with AA had 1 µL of 12.5 
mM AA added (to a sample concentration of 250 µM) 2 minutes before D2O addition. For samples 
involving the binding of MK-886, overnight pre-incubation at 4 °C was initiated by the addition 
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of 1 µL of 5 mM MK-886 in 100% ethanol to 50 µL of 50 µM FLAP to a final MK-886 sample 
concentration of 100 µM.  
 
H/D Exchange MS 
 H/D exchange was initiated by the addition of 45 µL of D2O to the sample (prepared by 
methods previously described) (1:10 dilution with D2O) at 24 °C. The deuterium-protein solution 
was incubated for time points ranging from 15 seconds to 8 hours at approximately 24 °C. H/D 
exchange was quenched with the addition of 50 µL of quench buffer (identified during peptide 
mapping) and dropping the temperature to 0 °C by putting the sample on ice. Pepsin (2 µL of 20 
mg/mL in H2O for 15-LOX and 2 µL of 10 mg/mL for FLAP) was added immediately after 
quenching and incubated on ice for 7 minutes. All samples were prepared individually and 
analyzed on the mass spectrometer on the same day. The resulting peptides were separated by 
reverse-phase HPLC on an ice-cold Phenomenex Aeris Peptide 3.6 µ XB-C18 50 x 21 mm column 
and eluted at a flow rate of 0.1 mL/min with a 15-minute gradient of 5-50% acetonitrile/H2O with 
0.4% formic acid for 15-LOX-2 and a 15-minute gradient of 5-75% acetonitrile/H2O with 0.4% 
formic acid for FLAP. Scans of m/z from 300 to 2000 were utilized for peptide detection on a 
ThermoFinnigan LTQ Linear Ion Trap with an ESI ionization source set in positive mode. 
Deuterium incorporation was observed as a shift in the centroid of the ion envelope for each 
peptide at varying time points. 
In order to correct for loss of deuterium that occurs during the chromatography step (back-
exchange) a 100% control was completed. This control was created by digesting 15-LOX-2 using 
the same conditions used for peptide identification and H/D exchange. The resulting  peptides were 
repeatedly lyophilized and subsequently incubated in D2O to ensure 100% deuteration of the 
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peptides, after which the peptides were frozen at -80 °C until analysis by MS. Peptides were 
injected onto the mass spectrometer using the same method utilized for time-point samples. In this 
control the back-exchange was calculated to be between 15-35% depending on peptide’s innate 
exchange rates, elution time, and length.  
The spectra from each H/D exchange sample were analyzed using the program 
HDExaminer (Sierra Analytics). This program determines the centroids of the isotope envelope 
for each peptide, at each time point, using a program-specific algorithm. HDExaminer identifies 
the peptide ion envelope using the parent mass, charge, and retention time of the peptide. After 
HDExaminer analysis, the peptide ion envelope identified by HDExaminer were manually 
confirmed by comparing the spectra to the peptide sequencing spectra generated during the peptide 
mapping. HDExaminer determines the number of deuterons incorporated onto each peptide using 
Equation 3, where D is the number of deuterons incorporated, N is the total number of 
exchangeable backbone amides, mt is the average mass of the peptide at the given time point, m0% 
is the mass of the non-deuterated peptide, and m100% is the mass of the fully deuterated peptide 
(back-exchange control).  
Equation 3.   D = N − (
mt−m0%
m100%−m0%
) 
Each sample was tested 2-3 times and deuterium incorporation for that peptide was 
averaged. The total number of deuterium incorporated was plotted verses time and fit to the sum 
of first-order rate terms as seen in Equation 4, in which D is the number of deuterons incorporated, 
N is the number of exchangeable sites, A and k are the amplitude and rate constants of the nth 
phase of exchange.  
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Equation 4.   D = N − A1e
−k1t − A2e
−k2t − A3e
−k3t … − Ane
−knt 
The exchange amplitude at time zero (Afast) represents the number of hydrogens that 
exchange within the first 15 seconds. The value of Afast is calculated by taking the differences 
between the sum of the fitted amplitudes in the intermediate kinetic phases (> 15 s) and the total 
number of exchangeable sites in the peptide. Inasmuch as Afast is an extrapolated value and not a 
fitted parameter, no errors are reported. Given that the errors in the fitted amplitudes A1, A2, and 
A3 are typically less than 10% the errors in Afast are estimated to be less than 20-30%. The 
calculated rates for H/D exchange will be classified into rapid, intermediate, and slow exchange 
categories. Peptides identified as displaying significant changes in deuterium incorporation 
between states were those that displayed a 10% or greater change in Afast or slow exchange rates. 
Due to the large number of identified peptides and different states tested, only the kinetic profiles 
for peptides that are important in understanding data interpretation are shown herein. The 
remaining kinetic profiles are shown in Figures 38-41 of the Appendix.   
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CHAPTER III 
 
EXAMINATION OF 15-LIPOXYGENASE-2 STRUCTURAL DYNAMICS IN SOLUBLE 
AND MEMBRANE ASSOCIATED STATES 
 
A crystal structure of 15-LOX-2 revealed that a Ca2+ binding site stabilized a hydrophobic 
loop between P74 and A86.107 This loop projects from the PLAT domain and is composed of a 
unique primary sequence when compared to other human LOXs (Figure 10). Dr. Marcia 
Newcomer’s laboratory suggested that Ca2+ binding may stabilize the loop in a position that allows 
it to be buried into the membrane upon 15-LOX-2 membrane association, however, this putative 
membrane association model required further studies to determine its validity.107 In this work, the 
structural dynamics of 15-LOX-2 in both soluble and membrane associated states were 
investigated to determine the impact of Ca2+ binding and membrane association on 15-LOX-2 
structure. 
 
Results 
Peptide mapping of 15-LOX-2 
Our optimization of the digestion procedure for 15-LOX-2 (protocol in Chapter 2) included 
testing different proteases at varying molar ratios, the addition of denaturants to the quenching 
buffer, and varying protein-protease incubation times. A pepsin digest with a 7 min digestion 
period, analyzed by tandem MS, created a peptide map providing 72% sequence coverage and 68 
measurable peptides ranging from 5 to 20 residues for the native 15-LOX-2 enzyme (Figure 15).  
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Figure 15. Peptide Map of 15-LOX-2. Peptides from 15-LOX-2 were generated by a pepsin 
digest, analyzed by tandem MS, and identified by the PEAKS computation program. Peptides with 
measurable ion envelopes in soluble 15-LOX-2 are shown by orange lines above the sequence and 
measurable peptides in nanodisc-associated 15-LOX-2 are shown by blue lines. Residues that are 
conserved in mammalian LOXs and thought to be part of substrate binding are in red while residues 
that coordinate the catalytic iron are in green. 
 
1   MAEFRVRVSTGEAFGAGTWDKVSVSIVGTRGESPPLPLDNLGKEFTAGAE  50
51  EDFQVTLPEDVGRVLLLRVHKAPPVLPLLGPLAPDAWFCRWFQLTPPRGG 100
101 HLLFPCYQWLEGAGTLVLQEGTAKVSWADHHPVLQQQRQEELQARQEMYQ 150 
151 QWKAYNPGWPHCLDEKTVEDLELNIKYSTAKNANFYLQAGSAFAEMKIKG 200
201 LLDRKGLWRSLNEMKRIFNFRRTPAAEHAFEHWQEDAFFASQFLNGLNPV 250
251 LIRRCHYLPKNFPVTDAMVASVLGPGTSLQAELEKGSLFLVDHGILSGIQ 300
301 TNVINGKPQFSAAPMTLLYQSPGCGPLLPLAIQLSQTPGPNSPIFLPTDD 350
351 KWDWLLAKTWVRNAEFSFHEALTHLLHSHLLPEVFTLATLRQLPHCHPLF 400
401 KLLIPHTRYTLHINTLARELLIVPGQVVDRSTGIGIEGFSELIQRNMKQL 450
451 NYSLLCLPEDIRTRGVEDIPGYYYRDDGMQIWGAVERFVSEIIGIYYPSD 500
501 ESVQDDRELQAWVREIFSKGFLNQESSGIPSSLETREALVQYVTMVIFTC 550
551 SAKHAAVSAGQFDSCAWMPNLPPSMQLPPPTSKGLATCEGFIATLPPVNA 600
601 TCDVILALWLLSKEPGDQRPLGTYPDEHFTEEAPRRSIATFQSRLAQISR 650
651 GIQERNQGLVLPYTYLDPPLIENSVSI 676                                            
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Addition of AA and nanodiscs decreased MS signals due to charge competition in ESI and 
also the competition of 15-LOX-2 peptides with peptides derived from the MSP component of the 
nanodiscs. Therefore, sequence coverage slightly decreased in samples containing these additives. 
Results for the most pertinent peptides for illuminating the roles of structural dynamics in 15-
LOX-2 regulation and function are presented herein. More of the H/D exchange kinetics data, not 
specifically discussed throughout this work, are shown in the Appendix to provide the overall view 
of 15-LOX-2 H/D exchange profile (Figures 38-41). The following nomenclatures were used in 
the description of our research: “peptide” being used when referring to an actual peptide identified 
in the protein digestion and “region” being used to refer at an area of the protein that may or may 
not correspond to an actual peptide.  
         
Spatial resolution of 15-LOX-2 structural dynamics 
The peptide backbone stability of partially water-exposed secondary structural elements 
that undergo local unfolding can be investigated by measuring deuterium incorporation onto the 
peptide backbone of 15-LOX-2 after 1 hour of H/D exchange. The level of deuteration of 15-LOX-
2 with no bound Ca2+ or AA after 1 hour of H/D exchange was mapped onto the crystal structure 
of human 15-LOX-2 (PDB entry 4NRE, which has Ca2+ bound to the PLAT domain and a substrate 
mimic, the detergent C8E4, bound to the active site in the catalytic domain) (Figure 16A).107 A 
wide range (from 5% to 90%) of levels of deuterium incorporation were observed for peptides 
from 15-LOX-2 following 1 hour of H/D exchange. This data indicates the two domains of 15-
LOX-2 exhibit significant differences in deuterium incorporation. In general, peptides derived 
from the PLAT domain, such as peptide 45-52 and 67-87, exhibit a high incorporation of deuterium 
ranging from 60% to 90%, indicating relatively high solvent exposure and flexibility, whereas 
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many peptides in the catalytic domain exhibit low incorporation of only 0%-20%, indicating 
limited solvent exposure and less flexibility (Figure 16A). Part of the PLAT domain that exhibited 
the highest deuterium incorporation (85%) was peptide 67-87, which is part of a hydrophobic loop 
that is projected from the PLAT domain in the 15-LOX-2 crystal structure.107 This loop is 
hypothesized to act as a hydrophobic anchor in 15-LOX-2 membrane association. Another 
interesting result is the high deuterium incorporation observed in peptide 117-134, indicating that 
the linker between the PLAT and catalytic domain is both flexible and solvent-exposed. 
 There are regions in the catalytic domain that exhibit high H/D exchange. The highest 
deuterium incorporation in the catalytic domain involves α-helix 2 (peptide 185-192) which is 
known to be flexible so that the active site can accommodate different substrates such as 
phospholipid-esterified AA (Figure 16B).131,132 The entrance of the active site in 15-LOX-2 
displays higher deuterium incorporation (peptide 419-438), indicating this region is flexible and 
also can play a role in 15-LOX-2 ability to bind ligands with bulky head groups.  As anticipated, 
peptides that are involved in coordination of the catalytic iron, such as peptide 366-383 and 548-
558, exhibit a low deuterium incorporation of only 5%, indicating that the region is highly 
protected from solvent exposure. The only iron-coordinating peptide that showed a higher 
deuterium incorporation level was the peptide that contains the C-terminal end of 15-LOX-2 
(peptide 671-676) (Figure 16B).  
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Figure 16. Structural dynamics of ligand- and substrate-free 15-LOX-2. (A) Backbone amide 
deuteration levels of 15-LOX-2 peptides following 1 hour of H/D exchange were mapped onto the 
15-LOX-2 crystal structure (PDB entry 4NRE)(11) to identify general flexibility and solvent 
exposure. Gray indicates regions that could not be identified. Peptides referred to in this work are 
designated by their sequence range. (B) Deuterium levels of the 5 helices that form the active site 
and coordinate the catalytic iron are shown. Helices are labeled by their numerical order in LOXs.   
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Figure 17. Impact of Ca2+ binding and membrane association on H/D exchange for the PLAT 
domain of 15-LOX-2. The number of deuterons incorporated into peptides vs time was plotted to 
obtain H/D exchange kinetics for 15-LOX-2 peptides in a Ca2+ free state (blue squares), Ca2+ 
bound state (red circle), and nanodisc-associated state (green triangle). Peptides are labeled by 
their sequence range and mapped onto the PLAT domain of 15-LOX-2 by color.  
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Structural dynamics in 15-LOX-2 upon binding Ca2+  
15-LOX-2 is a peripheral protein that translocates from the cytosol to the membrane upon 
binding Ca2+. There are two Ca2+ binding sites located on one face of the PLAT domain in 15-
LOX-2.  To investigate how the binding of Ca2+ might affect 15-LOX-2 structural dynamics and 
promote membrane association, full backbone H/D exchange kinetics of 15-LOX-2 were 
performed in the presence and absence of Ca2+. Due to low ion envelope resolution, peptides that 
contain residues of Ca2+ binding site 1 could not be analyzed. However, peptide 67-87, which had 
high ion envelope resolution and could be analyzed, is important in structuring Ca2+ binding site 2 
(Figure 17, panel C). Surprisingly, there are no significant changes in the H/D exchange kinetic 
profiles in this peptide upon Ca2+ binding. In fact, the only peptide to show a change in deuterium 
incorporation due to Ca2+ binding was peptide 92-104, which exhibited a small 8% reduction in 
deuterium incorporation during the first 5 minutes of H/D exchange (Figure 17, panel B). 
Comparison of H/D exchange for 15-LOX-2 and 15-LOX-2 with bound Ca2+ indicates there are 
no significant changes in the structural dynamics of the PLAT domain upon binding Ca2+. These 
results raise questions on how Ca2+ binding promotes membrane association in 15-LOX-2.  
 
Association of 15-LOX-2 with nanodiscs 
In addition to investigating how Ca2+ binding may affect the structural dynamics of soluble 
15-LOX-2, H/D exchange kinetics of 15-LOX-2 associated to a membrane substitute were 
collected to identify regions involved in membrane association or that undergo conformational 
changes upon membrane association. Dr. Marcia Newcomer’s lab demonstrated that 15-LOX-2 
associates to nanodiscs in a Ca2+ dependent manner.107  
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Figure 18. 15-LOX-2 binding to lipids on “strips” to screen for the lipid binding preference 
of this enzyme. PIP and SphingoStrips were used to identify the phospholipid 15-LOX-2 prefers 
to associate with. Detection of protein was completed with an alkaline phosphatase staining 
solution. The strips demonstrated that of the lipids represented in this experiment 15-LOX-2 
associates with the highest affinity to PS.    
 
Nanodiscs are model membrane systems that are believed to have a number of native 
membrane-like properties. They are formed by discoidal phospholipid bilayers that are encircled 
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by an amphipathic helical protein called the MSP and create ideal conditions for analyzing protein 
interactions with membranes. Therefore, 15-LOX-2 associated with nanodiscs was used to model 
15-LOX-2 associated to the cellular membrane in H/D exchange experiments. Preliminary 
experiments with PIP and SphingoStrips indicate that 15-LOX-2 preferably associates with PS 
over other phospholipids (Figure 18) and so this lipid was included as one of the lipid components 
of the nanodiscs used in this study.  
Prior to H/D exchange, 15-LOX-2 association to PS-containing nanodiscs was verified 
using SEC as monitored by a 280 nm UV-detector. An elution peak was observed at approximately 
8.8 mL when isolated nanodiscs were run on a Superose-12 10/300 GL column. Purified 15-LOX-
2 eluted at 13.7 mL, while the peak for 15-LOX-2 associated with nanodiscs in the presence of 
Ca2+ eluted at approximately 8.5 mL (Figure 19). Peak identities were confirmed using SDS-PAGE 
(Appendix, Figure 42). These results confirm that 15-LOX-2 associates with nanodiscs in the 
presence of Ca2+. 
 
Figure 19. Association of 15-LOX-2 with nanodiscs. SEC chromatography profiles showing 15-
LOX-2 association to nanodiscs. Free 15-LOX-2 eluted at 13.7 mL, but shifted to elution at 8.5 
mL when associated with nanodiscs.  
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H/D exchange of 15-LOX-2 associated with nanodiscs 
H/D exchange of Ca2+-15-LOX-2 in solution and associated with nanodiscs was compared, 
revealing only slight changes in H/D exchange kinetics when 15-LOX-2 is membrane-associated 
(Figure 17). Peptide 67-87, which is part of the hydrophobic loop proposed to act as a membrane 
anchor, showed a slight reduction in deuterium incorporation (12%) during the first 2 minutes of 
exchange for nanodisc-associated Ca2+-15-LOX-2 compared to Ca2+-15-LOX-2 in solution 
(Figure 17, panel C). Peptide 45-52 also experienced a slight change upon membrane association 
of Ca2+-15-LOX-2, its rapid exchange increased by only one deuteron when compared to Ca2+-15-
LOX-2 in solution. However, over long exchange times the deuteration level of nanodisc-
associated 15-LOX-2 remained constant, ending with only a slightly lower deuterium 
incorporation (Figure 17, panel D). No other peptides in 15-LOX-2 exhibited differences in their 
H/D exchange kinetic profiles when comparing soluble and nanodisc-associated Ca2+-15-LOX-2. 
These results indicate that membrane association has only a minimal effect on the structural 
dynamics of 15-LOX-2 and that no region of 15-LOX-2 is stably buried in the membrane.  
Alterations in the type of model membrane used for these experiments were investigated 
to try and promote a tighter association between 15-LOX-2 and the membrane substitute. 
Substituting DDM for nanodiscs as a membrane model and varying Ca2+ concentration yielded 
similar H/D exchange as for nanodisc-associated 15-LOX-2 (Figure 20). Addition of AA to the 
nanodiscs resulted in the same levels of deuterium incorporation (Appendix, Figure 43), indicating 
that the presence of substrate does not increase 15-LOX-2 association.  
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Figure 20. Effect of DDM micelles effect on deuterium incorporation. Deuterium incorporation 
was measured at 15 seconds for Ca2+-15-LOX-2 and at varying DDM concentrations to analyze 
whether the protein associates to DDM micelles. The blue squares represent the amount of 
deuterons incorporated at 15 seconds. The red line represents the deuterium incorporation at 15 
seconds for Ca2+-15-LOX-2. There are no significant differences in deuterium incorporation 
between Ca2+-15-LOX-2 in solution and Ca2+-15-LOX-2 in the presence of DDM.   
 
Discussion 
Conformational Dynamics of native 15-LOX-2 
Data on protein structural dynamics provided by H/D exchange MS is particularly useful 
when mapped onto 3D crystal structures. A crystal structure provides an indispensable “snapshot” 
of the protein conformation in a static state. Experimental data from H/D exchange MS can be 
used to characterize the local dynamics and motions of the protein of interest in solution at ambient 
temperature. Currently, there is only one crystal structure of 15-LOX-2.107 This structure has a 
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substrate mimic C8E4 bound to the active site. The PLAT and catalytic domains are dominated by 
stable secondary structures. The PLAT domain is composed of eight β-sheets in a barrel-like 
conformation, and the catalytic domain is composed of α-helical bundles (see Figure 16).133 H/D 
exchange data after 1 hour of deuterium incubation indicated the two domains in native 15-LOX-
2 in solution exhibited significantly different degrees of flexibility. The peptides derived from the 
PLAT domain exhibited relatively high levels of deuterium incorporation indicating that the PLAT 
domain is globally dynamic to the extent that the β-strands of the barrel become transiently free 
from their normal β-sheet hydrogen bonding patterns enabling facile H/D exchange (Figure 16). 
The interior region of the catalytic domain was very stable and protected from solvent exposure. 
One interesting observation is that the long loop that connects the PLAT domain and the 
catalytic domain exhibited high deuterium incorporation after 1 hour of H/D exchange (Figure 16). 
In all crystal structures of mammalian LOXs, the domains adopt a similar overall arrangement 
with the PLAT domain resting atop the catalytic domain, giving the LOXs a 100 Å long cylindrical 
topology.88,107,134 The two domains share a large interdomain interface and are interconnected by 
non-covalent interactions. This suggests the possibility of an extensive interaction interface 
between the two domains in solution. However, in this work, the peptide backbone on the loop 
(peptide 117-134) and peptides involved in the domain interface (peptide 92-104) exhibit a high 
deuterium incorporation level. This implies that they are both solvent exposed and highly dynamic, 
contrary to what might be supposed from the crystal structures, suggesting few or weak 
interactions between these domains in solution. This conclusion concurs with small angle X-ray 
scattering experiments, which suggested the PLAT domain can swing away from the catalytic 
domain while in solution.79  
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The H/D exchange after 1 hour observed in the 15-LOX-2 active site region revealed low 
exchange on the active site interior (α-helix 7 and α-helix 14) indicating well-ordered structures 
with few local structural fluctuations (Figure 16B). The higher levels of deuterium incorporation 
at the active site entrance and exterior (α-helix 2; peptide 185-191, α-helix 8; peptide 419-438 and 
α-helix 16; peptide 591-602) indicate moderate to high degrees of flexibility. This flexibility very 
likely allows for inhibitors such as RS7, observed in the crystal structure of rabbit 15-LOX-1 (PDB 
entry 1LOX), to access the active site 106. In addition, 15-LOX-2 is able to oxygenate intact 
phospholipids and cholesteryl esters.132 The flexibility of the active site is needed to accommodate 
the bulky head groups of the fatty acids. 
 
Significant structural changes are not required for 15-LOX-2 to associate to the membrane 
15-LOX-2 is located in the cytosol until binding of Ca2+ to the PLAT domain results in 
translocation to the membrane.135 This cellular compartmentalization is an important regulatory 
feature observed in LOXs. The nature of any structural changes that occur upon Ca2+ binding that 
promote LOX membrane association have yet to be identified. Previous H/D exchange studies 
with cytosolic phospholipase A2 (cPLA2) suggested that binding of Ca
2+ to the cPLA2 C2 domain 
resulted in an overall decrease in the domain flexibility in a manner that promotes translocation to 
the nuclear membrane.136 However, in this work, we found that the addition of Ca2+ to 15-LOX-2 
PLAT domain did not result in significant changes in the rate of deuterium incorporation into any 
part of the protein that we were able to analyze (Figure 17).  
In previous H/D exchange experiments with peripheral membrane proteins, such as cPLA2, 
regions of the protein that are stably buried in the phospholipid bilayer are shielded from H/D 
exchange.137 However, nanodisc-associated 15-LOX-2 did not exhibit significant differences in 
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H/D exchange kinetics compared to Ca2+-15-LOX-2 in solution (Figure 17). In fact, the only 
peptide to show a slight decrease in deuterium incorporation in nanodisc-associated 15-LOX-2 
was peptide 67-87 (Figure 17, panel B). This peptide spans the unique hydrophobic loop (P73-
A86) that protrudes from the PLAT domain and is proposed to act as a membrane anchor. The 
H/D exchange kinetics obtained in this study for nanodisc-associated 15-LOX-2 eliminates the 
possibility of the hydrophobic PLAT loop inserting deeply and stably into the membrane. The data 
leaves open the possibility of the loop being involved in membrane surface binding in a manner 
that still allows transient water accessibility and H/D exchange.  
 
15-LOX-2 preferentially associates with PS relative to other phospholipids  
An alternative explanation for how Ca2+ binding promotes 15-LOX-2 membrane 
association can be proposed based on our observation that Ca2+-15-LOX-2 preferentially 
associates with the anionic phospholipid PS over other phospholipids, including a number of others 
that also are anionic (Figure 18). It is plausible that binding of Ca2+ to the PLAT domain adds 
positive charge for association with PS, without changing the structure and dynamics of the 
protein. However, because 15-LOX-2 binds PS specifically over other anionic lipids, this 
electrostatic effect is also complemented by headgroup-specific recognition of the PS moiety. This 
proposed membrane-associating mechanism is similar to that proposed for select peripheral 
proteins with C2 domains such as protein kinase C. Structural comparison of the C2 domains of 
protein kinase C (PKC) in Ca2+-free and Ca2+-bound states lacked conformation changes upon 
Ca2+ binding. A crystal structure of PKCα in complex with Ca2+ and phosphatidylserine revealed 
that phosphatidylserine filled the incomplete coordination sphere of the Ca2+ and Ca2+ acted as a 
bridge between the C2 domain and the membrane.138 The C2 domain of PKCα has large negatively 
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charged regions, similar to the PLAT domain in 15-LOX-2. It is possible that binding Ca2+ to the 
anionic regions of 15-LOX-2 PLAT domain switches the electrostatic potential to promote 
interactions with the negatively charged head groups of PS.  
 
 
 
Figure 21. Comparison of membrane association domains in 15-LOX-2 and PKCα. 
Electrostatic maps of the (A) PLAT domain in 15-LOX-2 and (B) the C2 domain in PKCα show 
anionic regions in the domains that promote binding of Ca2+. It is plausible that binding calcium 
switches the electrostatic potential to promote membrane association to anionic phospholipids.  
 
 
The 15-LOX-2 preference for PS has several interesting biological implications. First, its 
preference for PS differs from previous LOX membrane association studies. To date the PLAT 
domain of 11R-LOX from Gersemia fruticosa is the only LOX for which the mechanism of 
membrane association has been extensively studied. That study used fluorescence resonance 
energy transfer (FRET) and surface plasmon resonance to monitor interfacial binding of 11R-LOX 
to and SUV composed of varying molar ratios of lipids.82 These studies showed that 11R-LOX 
A B 
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associated with vesicles containing phosphatidylethanolamine and anionic phospholipids. 5-LOX 
membrane association was also investigated by monitoring in vivo membrane association, which 
showed that 5-LOX primarily translocates to nuclear membranes rich with PC, a zwitterionic 
phospholipid.139 In addition, 5-LOX activity was monitored with AA present in PC vesicles. 
Addition of 10-20% PS resulted in decreased 5-LOX activity, which was interpreted to indicate 
the PS decreased 5-LOX membrane association as this is required for 5-LOX to acquire AA in 
intact cells.89 The differences in preferred membrane compositions for association of various LOX 
suggest different mechanisms for membrane binding throughout enzyme superfamilies that have 
PLAT domains. This is likely reflected by a comparison of the 15-LOX-2 primarily sequence with 
sequences of other LOX. 15-LOX-2 has a unique sequence from A74 to P84, which forms a 
hydrophobic loop, mainly composed of leucines and prolines, which protrudes from the PLAT 
domain. Other LOXs have conserved tryptophans in their corresponding primary sequence that are 
identified to be essential in membrane association.87,107,78  
 
Table 1. Preferred phospholipids of LOX upon membrane association. Common 
phospholipids that are connected with LOX membrane association are presented here to highlight 
the different charges of their head groups. In this work 15-LOX-2 was found to prefer PS upon 
membrane association. PS is the most prevalent anionic phospholipid in the plasma membrane.  
Phosphatidylcholine (PC)
Phosphatidylserine (PS)
Phosphatidylethanolamine (PE)
Phosphatidic Acid (PA)
0
0
-1
-1
Phospholipid Head Group Net Charge (pH 7.0)
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Another interesting implication of the 15-LOX-2 preference for PS upon membrane 
association is that PS is known to initiate several important cellular pathways. PS enriched 
membranes recruit proteins, such as kinases, small GTPases and fusogenic proteins, to the 
membrane for initiation of enzymatic activity.140 This regulatory mechanism is observed for 
conventional C2 domains, which are structurally and functionally similar to the PLAT domain. 
However, most C2 domains show broad preference for anionic phospholipids and not specifically 
PS.141 Previous studies imply that LOX recruitment to the membrane and enzymatic activity may 
be regulated by the lipids present.72,139 Therefore, it is plausible that increased presence of PS 
increases 15-LOX-2 activity in intact cells. This observation could also provide a connection 
between PS and its observed anti-inflammatory properties. Previous studies demonstrated that the 
addition of PS to IL-1β stimulated synoviocytes reduced production of inflammatory mediators, 
such as IL-6, IL-8 and PGE2.
142 In vivo studies using RA-induced murine models demonstrated 
that injections of PS containing liposomes reduced inflammatory responses.143 While part of the 
anti-inflammatory mechanism in this mouse model appears to be dependent on activation of 
peroxisome proliferator-activated receptors the full cellular pathway is unknown. If PS promotes 
15-LOX-2 membrane association, it is plausible that increased PS may promote 15-LOX-2 
association to the membrane, therefore increasing LX biosynthesis and promoting resolution of 
inflammation. 
 
Conclusions 
Backbone amide H/D exchange is an excellent tool for identifying flexible regions of 
proteins. For 15-LOX-2 in both cytosolic and membrane associated states, the PLAT domain is 
more flexible and solvent exposed than the catalytic domain. Moreover, the linker between the 
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domains is highly flexible, implying the PLAT domain may be able to swing away from the 
catalytic domain in solution. In addition, the lack of substrate specificity observed for 15-LOX-2 
can be explained by the flexibility of the active site exterior. The H/D exchange data presented in 
this study suggest a mechanism for 15-LOX-2 membrane association that depends on Ca2+ 
binding. The mechanistic model can be derived by combining insight from the 15-LOX-2 crystal 
structure, its preference for PS, and similarities in H/D exchange kinetics for Ca2+-15-LOX-2 
compared to Ca2+ free 15-LOX-2. As Ca2+ binding does not change the structural dynamics of the 
PLAT domain it is plausible that its role is primarily electrostatic, adding positive charge to anionic 
regions of the PLAT domain, which potentiates interactions with the negatively charge head group 
of PS. The membrane interaction may be stabilized by the hydrophobic loop interacting with the 
membrane surface in a way that still allows transient water accessibility to the peptide backbone 
in the loop. Overall, our results provide a detailed insight in 15-LOX-2 structural dynamics and 
challenge the previous hypothesis that conformational changes of the PLAT domain upon Ca2+ 
binding are responsible for membrane association.107 
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CHAPTER IV 
 
ANALYSIS OF 15-LIPOXYGENASE-2 CONFORMATIONAL CHANGES UPON LIGAND 
BINDING 
 
Knowledge regarding modes of substrate binding and related structural effects in LOX is 
limited. There have been significant difficulties obtaining a crystal structure of 15-LOX-2 with 
bound AA. AA is proposed to slide into the active site through hydrophobic interactions with α-
helix 2 and α-helix 8 (Figure 8). It is believed to adopt a U-shape conformation in the active site, 
as AA adopts this conformation in a mutated version of 5-LOX (PDB entry 3V99), whereas C8E4, 
a substrate mimic, also adopts a similar conformation in 15-LOX-2 although the position in the 
active site is different between the structures (PDB entry 4NRE).107,97 Our research focused on 
identifying areas of the active site that interact with 15-LOX-2 ligands and resulting structural 
effects in LOXs upon ligand binding.  
 
Results 
Structural dynamics of substrate binding in 15-LOX-2 
To map conformational changes that potentially occur upon substrate binding, H/D 
exchange experiments were performed with Ca2+-15-LOX-2 in the presence of AA. As Ca2+-15-
LOX-2 is active throughout the H/D exchange incubation times, the production of product (15-
HpETE) as a complication to interpretation of the data was a concern. Therefore, activity assays 
were conducted using the same buffer and protein-substrate molar ratio as in the H/D exchange 
samples. The activity assays revealed that only 10% of AA is converted to 15-HpETE by 15-LOX-
2 after 200 seconds. Therefore, we focused only on H/D exchange data collected during the first 
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120 seconds of deuterium incubation in 15-LOX-2 in the presence of AA. As an additional control, 
H/D exchange was performed for Ca2+-15-LOX-2 with bound 15-HpETE. 
 
Figure 22. Deuterium exchange in the catalytic domain in 15-LOX-2 upon lipid binding. H/D 
exchange was performed for 15-LOX-2 in 4 different states: (1) 15-LOX-2 with Ca2+ present (blue 
square); (2) 15-LOX-2 with Ca2+ and AA present (green diamond); (3) 15-LOX-2 with Ca2+ and 
15-HpETE present (red circle); and (4) Ca2+-free 15-LOX-2 with AA present (black triangle). 
Peptides exhibiting changes greater than 10% at 2 minutes of exchange are shown.  
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When Ca2+-15-LOX-2 is in the presence of AA or 15-HpETE, five peptides (45-52, 54-67, 
67-87, 185-191, and 418-438) demonstrate a similar and significant decrease in deuterium 
incorporation when compared to Ca2+-15-LOX-2 alone (Figures 22 and 23). Two of the peptides 
that demonstrated a reduction in deuterium incorporation were part of the 15-LOX-2 active site. 
The segment corresponding to α-helix 2 (peptide 185-191), which forms the exterior of the active 
site, displayed a 21% decrease in deuterium incorporation at 120 seconds of deuterium incubation 
relative to substrate free Ca2+-15-LOX-2 (Figure 22). Peptide 419-438 located at the active site 
entrance exhibited a 12% reduction in H/D exchange at 120 seconds of deuterium incubation 
relative to substrate free Ca2+-15-LOX-2 (Figure 22). Decreases in deuterium incorporation upon 
AA and 15-HpETE binding in the active site are likely due to shielding of hydrogen exchange 
triggered by lipid binding protecting the peptide backbone from solvent exposure. This indicates 
that both lipid substrate and product are binding in a similar manner to 15-LOX-2. As an additional 
control, deuterium incorporation after 15 seconds of H/D exchange was measured at increasing 
concentrations of AA to test if the reduction in deuterium incorporation in the presence of AA was 
due to AA micelle formation. The smooth dose-dependent trend over the critical micelle 
concentration of AA (70 µM)144 suggests that the deuterium incorporation profiles observed are 
not caused by the peptide backbone of 15-LOX-2 interacting with an AA micelle (Figure 24). 
One of the more interesting H/D exchange results observed in this work is that binding of 
either AA or 15-HpETE to the 15-LOX-2 active site in the catalytic domain induces a decrease in 
deuterium incorporation in peptides that are located in the PLAT domain (peptides 45-52, 54-76, 
and 67-87) (Figure 23). Peptide 67-87 showed a 32% reduction in deuterium incorporation after 
120 seconds of H/D exchange in Ca2+-15-LOX-2 with bound AA relative to Ca2+-15-LOX-2 alone 
(Figure 23). Peptide 45-52 experienced a 30% reduction in deuterium incorporation after 120 
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seconds of H/D exchange (Figure 23). This suggests that AA binding to the catalytic domain either 
reduces the conformational freedom of the PLAT domain or induces conformational changes that 
limit solvent exposure.  
 
Figure 23. Deuterium exchange in the PLAT domain in 15-LOX-2 upon lipid binding. 
Addition of substrate and product to 15-LOX-2 resulted in unexpected decreases in H/D exchange 
in the PLAT domain. H/D exchange was performed for 15-LOX-2 in 4 different states: (1) 15-
LOX-2 with Ca2+ present (blue square); (2) 15-LOX-2 with Ca2+ and AA present (green diamond); 
(3) 15-LOX-2 with Ca2+ and 15-HpETE present (red circle); and (4) Ca2+-free15-LOX-2 with AA 
present (black triangle). Peptides with changes greater than 10% after 2 minutes of exchange are 
shown.  
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Figure 24. AA dose dependence of deuterium incorporation. Deuterons incorporated after 15 
seconds of D2O incubation were measured and plotted vs concentration of AA. This showed a 
dose-dependent response with a smooth transition moving from below to above the critical micelle 
concentration of AA (70 µM)144. This indicates that decreases in deuterium incorporation observed 
at 250 mM AA are not dependent on AA micelle formation.  
 
To test if the reductions in deuterium incorporation in peptides derived from the PLAT 
domain in the presence of AA are Ca2+ dependent, 15-LOX-2 was chelated with EGTA before the 
addition of AA followed by H/D exchange experiments. Two of the three peptides in the PLAT 
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Ca2+ (Figure 23), suggesting that this peptide is destabilized upon Ca2+ removal in the presence of 
AA. This peptide is part of β-7, which is located close to the Ca2+ binding site, but does not have 
any amino acids that directly coordinate Ca2+.  
 
Structural studies of the allosteric regulation of 15-LOX-2 
Allostery is the process by which proteins transmit the effect of binding at one site to 
another, often distal, functional site allowing for regulation of enzymatic activity. Since allostery 
is a thermodynamic process, the communication across a protein can be facilitated by both static 
and dynamic conformational fluctuations.145 15-LOX-2 oxygenation of AA is positively 
allosterically regulated by the binding of 13-HODE.110 To identify the 13-HODE binding site and 
the structural mechanism of allostery in 15-LOX-2, H/D exchange MS studies were carried out for 
Ca2+-15-LOX-2 in the presence of 13-HODE, and 15-HpETE.  
When analyzing the H/D exchange kinetics it is important to consider that 13-HODE is the 
reduced product of 13-HpODE, which in turn is an enzymatic product of 15-LOX-2. Therefore, 
13-HODE can potentially bind to both the active and allosteric sites. H/D exchange kinetics for 
Ca2+-15-LOX-2 with 13-HODE bound revealed changes in deuterium incorporation in 5 peptides 
(45-52, 67-87, 117-134, 185-191, and 419-438) when compared to Ca2+-15-LOX-2 (Figure 25). 
Peptides 45-52, 67-87, and 185-191 all experienced a decrease in deuterium incorporation upon 
ligand binding. These peptides also exhibited reductions in deuterium incorporation upon 15-
HpETE binding, implying the ligands are binding in similar locations and inducing similar 
conformational changes. As 15-HpETE binds to the 15-LOX-2 active site, but does not 
allosterically regulate 15-LOX-2 the decrease in deuterium incorporation in these peptides are 
thought to be associated with binding to the active site.  
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Figure 25. Effects of ligand binding to 15-LOX-2. The H/D exchange kinetic profiles of 15-
LOX-2 are shown as a function of time. The y-axis represents the number of exchangeable sites in 
the peptide. Four different Ca2+-15-LOX-2 states are shown: (1) 15-LOX-2 with no ligand bound, 
(2) 15-LOX-2 with 250 µM AA, (3) 15-LOX-2 with 250 µM 15-HpETE, and (4) 15-LOX-2 with 
250 µM 13-HODE. The rate constants and amplitudes from this data are provided in Table 4.  
D
e
u
te
ro
n
s
 I
n
c
o
rp
o
ra
te
d
 
1
2
3
4
5
6
7
8
9
10 100 1000 10
4
10
5
92-104
0
1
2
3
4
5
10 100 1000 10
4
10
5
185-191
0
2
4
6
8
10
12
14
10 100 1000 10
4
10
5
67-87
0
1
2
3
4
5
6
7
8
10 100 1000 10
4
10
5
54-66
0
1
2
3
4
5
10 100 1000 10
4
10
5
45-52
0
0.5
1
1.5
2
2.5
3
3.5
4
10 100 1000 10
4
10
5
672-676
0
2
4
6
8
10
12
14
10 100 1000 10
4
10
5
419-438
0
2
4
6
8
10
12
10 100 1000 10
4
10
5
117-134
Time (seconds) 
   no ligand
  
= 
  AA = 
  15-HpETE = 
  13-HODE = 
 85 
 
An interesting observation from this data is that the deuterium incorporation for peptides 
45-52, 67-87, and 185-191 in Ca2+-15-LOX-2 with bound 15-HpETE is less than the deuterium 
incorporation for Ca2+-15-LOX-2 with bound 13-HODE (Figure 25). For example, peptide 67-87 
shows approximately 4 deuterons incorporated after 15 seconds of H/D exchange in the Ca2+-15-
LOX-2 complex with 13-HODE compared to approximately 2 deuterons incorporated in Ca2+-15-
LOX-2 complexed with 15-HpETE. Another, interesting result for the Ca2+-15-LOX-2/ 13-HODE 
complex is that peptides 117-134 and 419-438 exhibit increased deuterium incorporation when 
compared to Ca2+-15-LOX-2. This indicated the protein backbone becomes either more flexible 
or more solvent exposed due to conformational changes that occur upon ligand binding.  
 
Discussion 
Conformational changes in the 15-LOX-2 PLAT domain upon lipid binding 
Knowledge of substrate binding in LOX has significantly improved since the first 
mammalian LOX, rabbit 15-LOX-1, was crystalized in 1997.106 The active site in LOXs is 
hypothesized to be highly dynamic as binding of an inhibitor to rabbit 15-LOX-1 structure induced 
a 12 Å movement in α-helix 2 and a substantial rearrangement of the active site shape. In addition, 
15-LOX is able to oxygenate AA-containing phospholipids and cholesteryl esters, which implies 
the active site is able to adapt to bind ligands with bulky head groups.131 As previously discussed, 
the H/D exchange data in our research also indicates that the exterior of the active site is highly 
dynamic.  
In the H/D exchange experiments featured in this chapter that focus on substrate binding 
in Ca2+-15-LOX-2 we observe a decrease in deuterium incorporation at the exterior region of the 
active site (peptides 185-191 and 419-418) upon substrate binding. This implies that lipids in the 
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active site are coordinated by the exterior of the active site in a way that shields the peptide 
backbone from H/D exchange. An alternative explanation is that lipid binding reduces the 
flexibility of the active site exterior. Interestingly, there was no corresponding observable change 
in the H/D exchange in the interior of the active site. As these peptides experience low deuterium 
even incorporation in ligand free 15-LOX-2 it would be difficult to detect solvent shielding effects. 
Nevertheless, the lack of changes in H/D exchange in the active site interior in the presence of AA 
does, at the very least, suggest that the active site is not opened in a way that allows solvent 
accessibility upon substrate binding.  
AA-induced changes in H/D exchange kinetic profiles were observed in both the active site 
in the catalytic domain and select regions of the PLAT domain. Traditionally, PLAT and C2 
domains were primarily thought to function only as membrane associating domains.36 However, 
recent work suggests a plausible communication site between the PLAT and catalytic domains in 
LOXs that implies the PLAT domain may play a role in regulating LOX activity.72 There is a 
conserved π-cation interaction between a tryptophan in the PLAT domain and lysine or arginine 
in the catalytic domain observed in all mammalian LOX crystal structures. Moreover, multiple 
sequence alignments reveal the amino acids involved in this interaction are conserved throughout 
the enzyme superfamily (Figure 26). In 15-LOX-2, this interaction is between W109 on PLAT 
domain β-strand 7 and K175 on catalytic domain α-helix 2. A crystal structure of a truncated 
version of 12S-LOX that lacks the PLAT domain revealed significant positional shifts in α-helix 
2 when compared to other LOX crystal structures, implying the physical restraint imposed by the 
PLAT domain may play a role in positioning α-helix 2.83 In addition, a W98A mutation in 12/15-
LOX, which corresponds to W109 in 15-LOX-2 (see Figure 26), decreased the enzymatic turnover 
rate. This loss of activity was associated with changes in inter-domain orientations, as the 12/15-
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LOX molecular diameter increased and its thermal stability decreased. These studies imply an 
important role for PLAT and catalytic domain communication in the LOX catalytic mechanism.84 
                               
Figure 26. The conserved π-cation bridge that connects the PLAT and catalytic domains. A 
partial sequence alignment of the PLAT domain and the loop that leads to α-helix 2 is shown to 
demonstrate the amino acids that create the π-cation interaction. The amino acids that form the 
interaction are in blue, while other conserved amino acids are in red.  
 
 One of the more interesting results of this work was that there are changes im H/D 
exchange in the PLAT domain upon lipid binding to the catalytic domain, which supports the 
importance of the previously-hypothesized interdomain communication (Figure 27). Exactly how 
occupation of the active site alters the structure of the PLAT domain is not established by our data, 
but our results support the presence of important interdomain communications, as it appears lipid 
binding to the active site alters H/D exchange profiles in the PLAT domain. 
An alternative explanation for substrate-induced decreases in deuterium incorporation in 
the PLAT domain is AA binding to a secondary allosteric site that is proposed to be located 
between the PLAT and catalytic domains.110 LOX have been shown be allosterically regulated by 
their enzymatic products.146 However, the allosteric site in 15-LOX-2 is highly specific to 13-
HODE, the oxygenated product of LA. This site binds 13-HODE but not 15-HpETE or 12-
HpETE.110 This suggests it is unlikely that the decreases in deuterium incorporation in the PLAT 
domain are due to direct AA binding to the secondary allosteric site. In addition H/D exchange 
with 13-HODE was investigated and displayed differences in some unliganded 15-LOX-2 peptide 
15-LOX-2  99 GHLLFPCYQWL  170 LELNIKY   
15-LOX-1  89 DEVRFPCYRWV  160 LPVDERF    
 5-LOX    92 DYIEFPCYRWI  163 LPRDIQF 
12-LOX    88 AEVAFPCYRWV  160 LPPNMRF 
12-LOX-2  94 RIYHFPAYQWM  196 LNLNLRY 
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H/D exchange profiles, when compared to conditions with bound AA. Another explanation could 
be a nonspecific hydrophobic interaction between an AA micelle and the PLAT domain. However, 
this seems unlikely as the shielding of H/D exchange that results from the presence of AA was not 
observed when nanodiscs or other micelles were present (Figures 17 and 20).  
 
                         
Figure 27. The conserved π-cation bridge that binds the PLAT and catalytic domain. W109 
and K175 are invariant amino acids in the LOX superfamily and are proposed to play a role in 
domain communication. Here they are highlighted as the possible lynchpin linking decreases in α-
helix 2 H/D exchange upon AA binding to the decreases observed in the PLAT domain. 
 
 
 
α-2 
β-7 
W109 
K175 
= decrease 
= no change 
= not identified 
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Binding of 13-HODE to 15-LOX-2 changes the active site structure  
 Previous work by Dr. Theodore Holman’s laboratory demonstrated the role of 13-HODE 
as an allosteric regulator for 15-LOX-2. These studies were unable to identify the allosteric binding 
site or elucidate the molecular or structural mechanism of allostery.110 Binding of 13-HODE to 15-
LOX-2 activates the oxygenation of AA and inhibits the oxygenation of another 15-LOX-2 
substrate, GLA. This indicates the allosteric structural changes at the active site are able to 
discriminate between differences in the length and unsaturation of these ligands. The structural 
changes that result upon 13-HODE binding were investigated in this study by H/D exchange MS 
techniques. The differentiation between structural changes induced upon 13-HODE binding to the 
allosteric site and structural changes induced upon 13-HODE binding to the active site was 
achieved by comparing H/D exchange results to Ca2+-15-LOX-2 with bound 15-HpETE. 15-
HpETE binds to the active site, but does not allosterically regulate 15-LOX-2.   
Peptides 45-52, 67-87, and 185-191 from both the PLAT and catalytic domains 
experienced a decrease in deuterium incorporation upon 13-HODE and 15-HpETE binding 
indicating these effects are due to ligand binding to the active site and shielding of the peptide 
backbone from H/D exchange (Figure 28). In addition, comparison of deuterium incorporation in 
Ca2+-15-LOX-2 with bound 13-HODE and Ca2+-15-LOX-2 with bound 15-HpETE revealed less 
deuterium incorporation upon 15-HpETE binding in select peptides (Figure 25) implying 15-
HpETE has a greater shielding effect on the active site. This data corresponds with enzyme kinetic 
studies that show AA (converted to 15-HpETE) has a greater Km than LA (converted to 13-
HpODE). Therefore, these studies indicate that the active site favors the longer carbon chains with 
higher degrees of unsaturation.146  
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Figure 28. Comparison of H/D exchange kinetics upon 15-HpETE and 13-HODE binding to 
15-LOX-2. (A) The impact of ligand binding on the H/D exchange behavior of 15-LOX-2. The 
effects of 15-HpETE are shown in A, and the effects of 13-HODE are in B. Peptides exhibiting 
enhanced exchange are shown in orange while regions with decreased exchange are in blue. 15-
LOX-2 active site is emphasized by showing the binding of C8E4 to 15-LOX-2 active site. 
 
Protection from H/D exchange due to 13-HODE interacting with the peptide backbone of 
15-LOX-2 in the allosteric binding site was not observed. This could be due to the site being 
located in an area of 15-LOX-2 that does not have analyzable peptides or that 13-HODE is bound 
in a way that does not shield the peptide backbone from H/D exchange. Peptides 117-134 and 419-
438 undergo an increase in deuterium incorporation upon 13-HODE binding to Ca2+-15-LOX-2, 
indicating the peptide backbone is becoming more solvent exposed through increases in backbone 
flexibility or structural changes. The explanation for peptide 117-134 H/D exchange kinetics upon 
67-87 
54-66 
45-52 
67-87 
45-52 
117-134 
185-191 185-191 
419-438 419-438 
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13-HODE binding is not obvious as this peptide forms the unstructured linker between the PLAT 
and catalytic domain, and no previous work has implicated this part of the structure in regulation 
of enzymatic activity. The allosteric site is predicted to lie in the cleft located between the PLAT 
and catalytic domains. Therefore, it is possible that binding of 13-HODE forces the domains of 
15-LOX-2 into an arrangement that changes the orientation of the linker. Peptide 419-438 forms 
the exterior of the active site entrance. Increased deuterium incorporation implies the active site 
entrance is more solvent exposed or more dynamic. A common paradigm in positive allosteric 
interactions is modification of an active site that facilitates substrate binding.147 An opening of the 
active site in 15-LOX-2 would allow for an increase in substrate binding, however it does not 
explain how binding 13-HODE changes substrate specificity.   
Synthetic allosteric regulators present an opportunity to specifically regulate LOXs 
enzymatic activity. Changing the proportions of LOX products, as opposed to inhibiting the 
enzymatic activity could allow beneficial LOX activity to continue while still down-regulating the 
biosynthesis of inflammatory mediators. Further studies on 13-HODE allosteric regulation of 15-
LOX-2 are needed to fully interpret the H/D exchange data obtained in this study. 
 
Conclusions 
 Backbone amide H/D exchange analysis is an excellent tool to map the structural dynamics 
of purified protein targets upon ligand binding. Differentiation between direct effects of ligand 
binding and the impact of binding on global conformational dynamics is difficult and requires 
previous structural and molecular studies for interpretation. One of the more intriguing results from 
this study is that despite the lack of strong conformational coupling between the PLAT and 
catalytic domains, the data presented in this study nevertheless suggest that binding of AA to the 
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active site plays a role in regulating the structural dynamics of the PLAT domain. In addition, our 
H/D exchange studies with allosteric regulator, 13-HODE, suggest a structural mechanism for 
allostery, in which binding of 13-HODE results in the increased flexibility of the active site 
entrance. The H/D exchange kinetics reported here presents the first physical evidence for the role 
of structural dynamics in the enzymatic and allosteric mechanisms of 15-LOX-2.  
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CHAPTER V 
 
EFFORTS TOWARDS DETERMING 5-LIPOXYGENASE AND 5-LIPOXYGENASE 
ACTIVATING PROTEIN COMPLEX INTERACTIONS 
 
5-LOX is the only identified LOX that requires complex formation with a membrane 
scaffolding protein (FLAP) for optimal activity in intact cells. FLAP is an integral membrane 
protein that is hypothesized to facilitate the transfer of AA from the nuclear membrane to 5-LOX 
for conversion to 5-HpETE and initiation of the LT biosynthesis pathway. However, this putative 
role of FLAP requires additional information for verification. The AA binding site in FLAP and 
the protein-protein interaction sites in the 5-LOX-FLAP complex have not been identified. This 
work sought to use H/D exchange to elucidate the protein and ligand interactions in this important 
protein complex. 
 
Results 
Expression and Purification of FLAP 
Expression and purification protocols for recombinant 5-LOX and FLAP have been 
published;116,88 however, these protocols are hindered by low yields for FLAP and loss of 
enzymatic activity for 5-LOX. Therefore, the initial step of this investigation was to optimize 
protein expression and purification. Increased FLAP expression was achieved by expression trials 
utilizing differing expression vectors, competent cells, growth media, and induction points. 
Expression trials with different vectors revealed that vectors with low copy numbers (pET-28b and 
pET-21b) increased FLAP expression when compared to a vector with a high copy number 
(pUC57). Competent cells that are selected for increased membrane protein expression, such as 
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C41(DE3) and C43(DE3), increased FLAP expression when compared to the standard BL21 cells 
used in the previously published protocol.116 Expression tests with different types of growth media 
showed minimal media supplemented with glucose as a carbon source, and casamino acids, 
increased FLAP expression compared to the nutrient rich Terrific Broth and Luria Broth. 
Combining the data from the expression trials led to a protocol for optimal FLAP expression. A 
gene encoding full-length FLAP with a C-terminal His-tag and optimized codons was cloned into 
the pET-21b vector for E. coli expression. This vector was transformed into C43(DE3) competent 
cells and cells were grown at 37 °C in minimal media. Recombinant protein expression was 
induced with 1 mM IPTG when OD600 reached approximately 0.4.  The optimized protocol 
described here produced between 2 and 5 mg of FLAP in 9 L of cell culture (Figure 29). 
Figure 29. SDS-page gel of purified FLAP. FLAP was eluted from a gravity flow Ni-NTA 
column with an elution buffer containing 200 mM imidazole. 5 mL fractions were collected and 
run on an SDS-PAGE gel. All fractions were concentrated and used for FLAP experiments.   
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Purification of FLAP was accomplished by ultracentrifugation of the cell lysate to isolate 
the membrane fraction and subsequent solubilization of the membrane fraction in detergent 
micelles. To prevent protein aggregation, detergent screening was completed with different 
nonionic or zwitterionic detergents. The structural integrity and oligomeric state of FLAP were 
investigated by size exclusion chromatography (Figure 30). Elution from a High-Prep 16/60 
Sephacryl-200 HR column was monitored by absorbance at 280 nm. A monodisperse signal peak 
was observed at 45 mL, which corresponds to an approximate Stokes radius of 5 nm. This radius 
reflects the homotrimer formation of FLAP. Fractions were collected between 40 to 50 mL for 
further studies (Figure 30).  
 
Figure 30. Size exclusion chromatography of FLAP. FLAP was purified on a High-Prep 16/60 
Sephacryl-200 HR column to analyze FLAP size homogeneity. FLAP eluted with a Stokes radius 
of 5 nm corresponding to a FLAP homotrimer.  
 
Activity of 5-Lipoxygenase 
The published protocol for expressing and isolating 5-LOX produces sufficient yields for 
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completed in this work did not affect the protein yield. However, 5-LOX has been observed to lose 
activity after purification.86 Therefore, 5-LOX was mutated in previous work to increase the 
enzymatic half-life. The mutated version of 5-LOX, Stable 5-LOX, was used in these studies, but 
there was an inconsistency in activity between various protein purification batches. The highest 
specific activity measured was 35 
nmol
min·mg
 which is significantly less than the previously published 
kinetic data.87 To observe the time dependence of the enzymatic activity, 5-LOX activity was 
monitored 1, 8, and 20 hours after purification and stored at 4 °C in between time points. The 
specific activity was reduced by half after 8 hours and decreased to less than 1
nmol
min·mg
 after 20 
hours. Addition of oxygenated product has been shown to increase LOX activity by activating the 
catalytic iron.86 However, in this study addition of 13-HODE and 15-HpETE to 5-LOX activity 
assays did not increase the specific activity of 5-LOX.   
 
Figure 31. 5-LOX dual activity. The UV-Vis spectrum of 5-LOX used for activity assays shows 
several peaks, with the first peak at 238 nm corresponding to the HpETE product and the second 
peak at 270 nm corresponding to hydrolysis products of LTA4.   
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Figure 32. 5-LOX loss of activity. (A) Formation of the HpETE product plotted vs time to 
determine 5-LOX activity. Protein stored at 4 °C was tested at different time points after the final 
purification step to observe loss of 5-LOX activity over time. (B) Testing the effect of adding 
oxidized lipids to reactive the catalytic iron on 5-LOX activity assay. No significant increase in 5-
LOX activity was observed.    
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Figure 33. Preliminary Peptide Map of 5-LOX. Peptide map created by pepsin digest of 5-LOX. 
Peptides were separated, ionized, and fragmented using HPLC coupled to MS/MS. Peptides were 
identified using the computational program PEAKS.   
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Peptide mapping of FLAP was completed in a manner similar to that of 5-LOX, but was 
complicated by the presence of detergent. Detergents suppress the ionization of sample through 
charge competition in ESI. Therefore, initial detergent trials with various concentrations of DDM 
and CHAPS were completed to find the minimal concentration of each detergent required to avoid 
protein aggregation. FLAP was stable at 4 °C for several days in 0.05% DDM and 0.7% CHAPS. 
FLAP in DDM micelles provided greater peptide coverage compared to FLAP in CHAPS micelles 
and was used in peptide mapping optimization trials. However, FLAP still experienced 
consistently low sequence coverage. Adding denaturing agents such as urea and guanidine 
hydrochloride increased the peptide coverage from approximately 30% to 50%. The highest 
sequence coverage was obtained with FLAP stored in 20 mM Tris, 300 mM KCl, 2.5% glycerol, 
1 mM DTT, 0.05% DDM, pH=7.5. A 1:1.5 FLAP: pepsin molar ratio and a 7 minute digestion 
time provided 54% sequence coverage. Due to low ion envelope resolution, only select peptides 
could be analyzed in subsequent H/D exchange experiments; therefore the coverage dropped to 
35.4%.  
 
Figure 34. Peptide Map of FLAP. Peptide map created by pepsin digestion of FLAP. Peptides 
that were identified and had measurable ion envelope resolutions are labeled in blue and were used 
in subsequent H/D exchange studies. Peptides in black were identified by fragmentation but could 
not be analyzed due to low m/z signal.  
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H/D exchange of native and ligand bound FLAP 
H/D exchange experiments with FLAP were completed with the limited peptide map to 
determine structural dynamics in regions of the FLAP trimer. The levels of deuteration for six 
peptides were analyzed for FLAP without ligand bound. Several of the peptides (12-18, 18-25, and 
150-159) demonstrated less than 20% deuteration after 2 hours of H/D exchange (Figure 35). This 
indicates the peptides are protected from solvent exposure by interactions due to stable secondary 
structure or burial in detergent micelles. Peptide 42-50 is 75% deuterated during this time period, 
indicating it is highly flexible and partially solvent exposed (Figure 35). Peptide 49-67 experienced 
a significant increase in deuterium incorporation between 15 and 60 seconds, indicating local 
fluctuations in folding that allow solvent to access a protected region of the protein. (Figure 36)  
When FLAP was in the presence of AA (250 µM), only one of the six peptides showed a 
difference in deuterium incorporation over 2 hours of H/D exchange. Peptide 49-67 showed a 
significant decrease in the rate of deuterium incorporation at the 15 and 60 second time points, 
indicating this area of the protein either undergoes conformational changes that leads to solvent 
protection or is involved with ligand binding (Figure 36). Data collection with FLAP in the 
presence of inhibitor MK-886 (100 µM) was complicated by low signal. When FLAP was in the 
presence of MK-886, only peptides 12-18, 18-25, 42-50, and 150-159 could be measured for 
deuterium incorporation (Figure 36). All of these peptides showed similar deuterium incorporation 
for native and MK-886 bound FLAP, indicating inhibitor binding does not change the structural 
dynamics for the segments from which these peptides were derived.  
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Figure 35. Structural dynamics of apo-FLAP. Deuteration levels following 2 hour of incubation 
in D2O in apo-FLAP are mapped onto the crystal structure (PDB entry 2Q7R, with LT biosynthesis 
inhibitor MK-591 bound) to provide information on general flexibility and solvent exposure. Gray 
indicates that peptides were not identified in that area. (A) FLAP monomer with peptides referred 
to in this work designated by their sequence range. (B) FLAP trimer. (C) View from cytosol of 
FLAP. (D) View from lumen of FLAP.  
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Figure 36. H/D exchange profiles for FLAP peptides. Deuterium incorporation at 15, 60, 600, 
and 7,200 seconds was measured and plotted for each peptide. Three different states of FLAP were 
tested; (1) apo-FLAP, (2) FLAP with AA bound, and (3) FLAP with MK-886 bound.     
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expression tests. These tests indicated that use of competent cells optimized for membrane protein 
expression dramatically increased FLAP expression. C43 competent cells overexpress AtpF, the 
E. coli β-subunit of the H+-ATP synthase. This results in a large network of internal membranes 
providing a suitable environment for membrane protein folding. We found that plasmids with high 
copy numbers were unfavorable for expression, most likely due to rapid protein production and 
the subsequent cell death associated with toxicity. The protocol established in this work produced 
approximately 2 to 5 mg of FLAP from 9 L cell cultures. Proper folding and trimer formation for 
FLAP was indicated by size exclusion chromatography.  
 
Recombinant 5-LOX activity significantly decreases after protein purification  
The specific activity observed for 5-LOX in these studies was inconsistent and significantly 
less than previously reported.88 One possible explanation for low 5-LOX activity may be the 
method of measuring product formation in this work. The UV-Vis spectrometer assay monitors 
the absorbance of the conjugated double bonds formed in the HpETE product at 238 nm. 5-LOX 
is a dual function enzyme that transforms 5-HpETE to LTA4, the hydrolysis products of which 
have a max absorbance at 270 nm (Figure 31). Low and inconsistent activity observed in 5-LOX 
may be due to structural damage leading to loss of the catalytic iron coordination. 
 An alternative explanation for 5-LOX loss of activity is an inactive oxidation state of the 
catalytic iron upon 5-LOX purification. LOX kinetics have demonstrated a relatively long lag 
phase preceding steady-state kinetics due to the oxidation state of the catalytic iron. When 5-LOX 
is in an inactive state, the catalytic iron is in the ferrous state and it does not oxidize to a ferric state 
in the presence of molecular oxygen. In vivo, it is hypothesized that autoxidation of substrates 
leads to a small amount of non-enzymatically produced LOOH. These LOOH are able to oxidize 
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the catalytic iron to the active Fe3+ oxidation state.130 In these studies, addition of 13-HpODE and 
15-HpETE to activity assays did not significantly increase 5-LOX enzymatic activity, indicating 
the loss of activity observed for 5-LOX is most likely due to structural integrity as opposed to the 
catalytic iron (Figure 32).  
 
AA binding results in shielding of the FLAP hydrophobic cavity from H/D exchange 
Due to low peptide coverage in FLAP, minimal H/D exchange data could be analyzed 
(Figure 34). The detergents used to solubilize membrane proteins contribute to suppression of ion 
generation in ESI. Ion suppression results from the presence of less volatile compounds changing 
the efficiency of droplet formation or droplet evaporation in ESI, decreasing the amount of charged 
ions in the gas phase that reaches the detector, thereby lowering sample signal.149 Multiple attempts 
at decreasing detergent concentration in FLAP H/D exchange samples and adjusting MS 
parameters did not increase peptide identification or improve the ion envelope signal in H/D 
exchange.  
Little insight has been obtained regarding how AA binds to FLAP. The H/D exchange 
studies in this work provided some evidence. We observed a decrease in deuterium incorporation 
in peptide 49-67 upon addition of AA to FLAP (Figure 36). The remaining peptides analyzed do 
not experience any changes in H/D exchange profiles. Mapping the H/D exchange data onto the 
crystal structure of FLAP (that has inhibitor MK-591 bound) indicated that the central cavity of 
FLAP experienced protection from H/D exchange upon AA binding (Figure 37). Due to the 
inherent complications in interpreting H/D exchange data, the decrease could be due to ligand 
binding to this peptide or conformational changes upon AA binding, resulting in less solvent 
exposure. Previously published radioligand binding assays indicated the AA binding site overlaps 
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with the binding site for MK-591, which is between helix 1 on one monomer and helix 4 on the 
adjacent monomer in the FLAP homotrimer.150  
Figure 37. AA binding induces changes in H/D exchange in FLAP. Effects of AA binding to 
FLAP are mapped onto the FLAP crystal structure (with MK-591 bound, PDB entry 3O8Y). 
Peptides that experienced decreases in deuterium incorporation are in blue. Peptides that did not 
experience changes in deuterium incorporation are in orange, and peptides that are not identified 
are in gray.     
 
This limited information on the AA binding site supports both proposed explanations of 
the H/D exchange data. The indole moiety of MK-591, which binds in a similar position as MK-
886, is directed towards helix-2 (which contains peptide 49-67 and it part of the hydrophobic 
cavity); therefore AA could be directly interacting with this helix upon binding (Figure 37).116 
Alternatively, FLIM studies completed with an acceptor fluorophore on the C-terminus of FLAP 
and a donor fluorophore on the N-terminus indicated substrate induced changes in the orientation 
of the termini, supporting the hypothesis that the orientations of the TM helices shift upon AA 
A B 
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binding. It is plausible that changes in helical orientations lead to different conformations of FLAP 
that decrease solvent accessibility to the hydrophobic cavity.34 A more complete peptide map of 
FLAP would provide essential information for a specific explanation of the H/D exchange data 
collected.  
 
Conclusions  
This work has established an optimized expression protocol and a purification method that 
maintains proper membrane protein folding for FLAP. H/D exchange studies with 5-LOX were 
prevented due to structural degradation of 5-LOX leading to decreased activity over the time 
periods required for H/D exchange. Additional experiments are needed to establish a more stable 
form of 5-LOX that maintains its enzymatic activity and structural components. Deuteration levels 
of peptides after 2 hours of D2O incubation in FLAP indicate that local structural fluctuations allow 
solvent to access the hydrophobic cavity formed by the FLAP trimer. The hydrophobic cavity 
experiences significant decreases in deuteration upon AA binding, indicating that AA binds to the 
cavity, resulting in protection of the protein backbone from H/D exchange. An alternative 
explanation is that AA binding induces conformational changes that prevents solvent accessibility 
to the hydrophobic cavity. Additional experimental methods such as utilizing a peptide trap to 
remove detergent from FLAP H/D exchange samples before MS injection could be used to 
increase sequence coverage in the FLAP peptide map and improve ion envelope signal to complete 
the partial data collected in this study.  
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CHAPTER VI 
 
CONCLUSIONS 
 
 Inflammation is part of the protective immune response that is important in the healing 
process.  However, when not properly regulated, inflammation can trigger or contribute to a variety 
of diseases. Therefore, a large focus in pharmaceutical development is on therapeutics that regulate 
inflammation. This includes targeting the actions of proteins involved with the synthesis of 
eicosanoids. Eicosanoids are potent lipid mediators of inflammation. Two protein superfamilies 
involved in the biosynthesis of eicosanoids are the LOX and MAPEG superfamilies. This work 
focused on analyzing the structure and function of three proteins in these superfamilies, 15-LOX-
2, 5-LOX, and FLAP. There is a large amount of information available on the structure and 
biological activity of these proteins, but information on the protein structural dynamics that play a 
role in ligand binding and LOX membrane association has been limited. Therefore, this work 
utilized H/D exchange MS to analyze 15-LOX-2 structural dynamics upon ligand binding, and 
membrane association. Moreover, the preliminary studies completed in this work with 5-LOX/ 
FLAP protein and ligand interactions provide directions for future work.   
 
15-LOX-2 
 We initiated these studies using H/D exchange MS to determine secondary structure 
flexibility and solvent exposure in native 15-LOX-2. Mapping the deuterium incorporation levels 
of excised 15-LOX-2 peptides onto the crystal structure of 15-LOX-2 led to several interesting 
observations for the possible roles of structural dynamics in 15-LOX-2 function.107 The PLAT 
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domain is highly flexible, whereas the catalytic domain is much more ordered. In addition, H/D 
exchange profiles revealed the importance of structural dynamics in the exterior of the active site 
for the observed substrate promiscuity in 15-LOX-2. Moreover, the deuterium incorporation in the 
linker between the domains and in the domain interface suggests the likelihood of a high-degree 
of inter-domain flexibility. Protein dynamics upon Ca2+ binding were also investigated. However, 
no significant differences in H/D exchange were observed, indicating that 15-LOX-2 does not 
undergo structural changes upon binding Ca2+. 
 We completed further analysis by comparing the H/D exchange kinetics of Ca2+-15-LOX-
2, both in solution and when the complex was associated with membrane-mimetic, nanodiscs. The 
H/D exchange profiles of peptides derived from nanodisc-associated Ca2+-15-LOX-2 did not 
significantly differ from soluble Ca2+-15-LOX-2, indicating that significant structural changes are 
not required for membrane association. The hydrophobic loop that protrudes from the PLAT 
domain (Figure 17), observed in the crystal structure, is not deeply buried in the membrane. 
Overall, our results challenge the previous hypothesis that Ca2+ binding induced-structural changes 
of the PLAT domain in 15-LOX-2 promote membrane association. An alternative method of 
membrane association is suggested in this work, in which the binding of Ca2+ changes the 
electrostatic potential of the PLAT domain to positive without changing the structural dynamics 
of 15-LOX-2. This allows the PLAT domain to interact with the negatively charged head group of 
PS. Further experiments on 15-LOX-2 membrane association are needed to assess this suggested 
model of membrane association.   
 In addition to investigating structural changes upon membrane association, we used H/D 
exchange MS to test the impact of substrate and allosteric ligands on 15-LOX-2. Addition of AA, 
and 15-HpETE resulted in shielding from H/D exchange in select peptides derived from the 15-
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LOX-2 active site and PLAT domain when compared to ligand free Ca2+-15-LOX-2. The changes 
in H/D exchange between the states were not Ca2+ dependent. There is no previous structural 
evidence for AA or its oxygenated products directly interacting with the PLAT domain, which led 
me to conduct several additional control experiments. The deuterium incorporation was observed 
to be dose dependent with a smooth decrease in deuterium incorporation associated with increased 
AA concentrations, indicating the changes in H/D exchange are not due to interaction with an AA 
micelle. Moreover, involvement of an unidentified allosteric binding site for AA seems unlikely 
as 15-HpETE binding also induces changes in H/D exchange. Previous studies found that 15-
HpETE does not allosterically regulate 15-LOX-2 activity, and the allosteric site is highly specific 
for 13-HODE.110,151 An alternative explanation is that binding of AA to the active site could 
regulate the structural dynamics of the PLAT domain. This data is most intriguing, particularly in 
light of the lack of strong structural coupling between the PLAT and catalytic domains. 
 The structural dynamics involved with the allosteric regulation of 15-LOX-2 oxygenation 
of AA was also investigated by H/D exchange MS. In these studies Ca2+-15-LOX-2 and Ca2+-15-
LOX-2 with 13-HODE bound were compared. The data did not indicate the location of the 13-
HODE allosteric binding site but did suggest a possible structural mechanism of allostery. The 
entrance of the active site appears to become more dynamic upon the binding of 13-HODE, 
suggesting that the active site is opened to increase substrate binding and promote 15-LOX-2 
activity. The H/D exchange kinetics also implied that the linker between the PLAT and catalytic 
domain is affected by 13-HODE binding, suggesting that the interdomain conformations are 
changed during allosteric regulation. This work suggests that the structural dynamics of 15-LOX-
2 play an important role in its enzymatic activity and allosteric regulation. Pharmaceuticals that 
alter the structural dynamics of 15-LOX-2, as opposed to a substrate antagonist that block substrate 
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binding, could lead to highly specific regulation of 15-LOX-2 activity. Our data suggest that it is 
plausible a drug that shifts the inter-domain conformation or decreases the flexibility of the active 
site could be a promising treatment for diseases that are associated with 15-LOX-2.       
 
FLAP and 5-LOX 
 Previous studies have shown a direct binding interaction between 5-LOX, and FLAP.115 In 
addition, a direct interaction between AA and FLAP has been observed.34 Combining this 
knowledge with the results of other studies can create a working model of how the 5-LOX-FLAP 
complex functions: Substrate AA that is trapped in the membrane binds to FLAP, which is an 
integral membrane protein. FLAP then facilitates AA transfer from the membrane to the active site 
of 5-LOX located above the membrane surface. Here we sought to use H/D exchange MS to 
analyze 5-LOX and FLAP protein-protein and protein-ligand interactions. We initiated this project 
by completing expression trials that lead to an optimization of FLAP expression in E. coli. 
Competent cells specialized for expressing toxic proteins, such as membrane proteins, were used.  
We also systematically tested expression conditions. These efforts led to greatly increased FLAP 
expression that facilitated H/D exchange experiments. However, this project was greatly hindered 
by loss of 5-LOX enzymatic activity upon protein purification. Another complication was the 
suppression of ion generation in ESI during peptide mapping for FLAP from the detergents used 
to solubilize FLAP. Nevertheless, a partial peptide map of FLAP provided limited H/D exchange 
data that allowed the identification of a putative AA binding location in the hydrophobic cavity 
formed by the FLAP homotrimer. The data also suggests that AA enters the cavity through the 
small opening between the TM helices. This is interesting because the passage of AA through this 
cavity in route to the 5-LOX active site is a key component of our working model for the 
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mechanism of FLAP/5-LOX action. This work is the first to identify regions of FLAP that interact 
with AA, which is a crucial step in structure-based drug development. While these results are 
limited, they do pave the way for possible future studies.     
 
Future Studies 
 In this work we found that changes in structural dynamics are not needed for 15-LOX-2 
membrane association. We also completed experiments with PIP and SphingoStrips to reveal that 
15-LOX-2 preferentially associated to PS. However, binding of 15-LOX-2 to PS in actual 
membranes or model membranes such as nanodiscs has not yet been verified and additional 
experiments are needed. For example, we could repeat our SEC experiment that verified binding 
of 15-LOX-2 to PS-containing nanodiscs (Figure 19), using nanodiscs that do not contain PS. 
Isothermal titration calorimetry can be used to measure the dissociation constant (KD) for 15-LOX-
2 with unilamellar vesicles with PS and anionic phospholipids at varying molar ratios to confirm 
15-LOX-2 phospholipid preference. Surface plasmon resonance is an alternative technique that 
could be used to determine the KD for 15-LOX-2 with vesicles. This technique has the advantage 
of “real time” kinetics, however, it requires a Biacore instrument and biosensor chips with the 
immobilized lipid vesicles.152 In addition, a comparison of 15-LOX-2 structural dynamics upon 
membrane association with other human LOXs such as human 5-LOX, 12-LOX, and 12/15-LOX, 
would be interesting. Alignment of the primary sequence in the PLAT domains in these proteins 
suggest different mechanism for membrane association from LOX to LOX (Figure 10). Performing 
H/D exchange MS on these various LOXs in soluble Ca2+ free, soluble Ca2+ bound, and Ca2+ 
nanodisc-associated states would provide evidence needed to determine the degree to which LOX 
superfamily members differ in terms of  membrane association mechanism.  
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Much of the data presented in this study could be further illuminated if additional crystal 
structures of 15-LOX-2 were determined under conditions that are similar to those used in some 
of our H/D exchange experiments. For example, this work suggest that 13-HODE may positively 
allosterically regulate 15-LOX-2 activity by increasing the fluctuations of the active site entrance, 
allowing for facile substrate binding. However, a direct binding site for 13-HODE was not 
identified. A crystal structure of 15-LOX-2 with 13-HODE bound to the allosteric site would 
provide information on the molecular mechanism of allostery and could assist with the 
interpretation of the H/D exchange MS results in this work.  
Our work supports the notion that there is communication between the PLAT and catalytic 
domain. The role interdomain allostery plays in 15-LOX-2 biological function can be further 
investigated by completing site mutagenesis of K175 or W109 to disrupt the π-cation interaction. 
Analysis of the mutated 15-LOX-2 catalytic properties, in addition to analysis of its structure and 
structural dynamics, will provide essential information on the role of the PLAT domain in 15-
LOX-2 activity. 
Studies are needed to further investigate the 5-LOX and FLAP protein complex and 
complex-ligand interactions. Alternative expression systems for 5-LOX may assist in protein 
folding and allow post-translational modifications that improve 5-LOX structural stability. H/D 
exchange studies with FLAP could be improved by ultra performance liquid chromatography 
(UPLC). UPLC employs smaller particle sizes in ESI to produce superior resolution, speed, and 
sensitivity and recent work demonstrates its compatibly with H/D exchange MS methods.153 In 
addition, methods that remove of non-ionic detergents prior to sample injection are being 
optimized.154 Both of these methods could improve the resolution of the peptide ion envelope and 
 113 
 
improve the fragmentation data that leads to improved sequence coverage. These methods can be 
supplemented with other structural dynamics-dependent labeling techniques coupled with MS. 
 
Concluding Remarks 
 The study of inflammation has progressed from treating inflammatory symptoms with 
natural products to developing a molecular understanding of the cellular pathways involved in 
inflammation. Although the body of knowledge related to inflammation is already vast each new 
study on key mediators brings the scientific community a step closer to being able to properly 
regulate the cellular pathways that lead to harmful inflammatory symptoms. This work focused on 
the structural dynamics of three proteins involved in the biosynthesis of a few subclasses of 
eicosanoids, which is an essential part of these cellular pathways. These studies are representative 
of the fact that we are now in the stage of not only observing the biological functions of proteins 
involved in inflammation, but also being able to utilize their structure and structural dynamics as 
the basis for designing molecules to target them for therapeutic purposes. It is my hope that the 
work of this dissertation will contribute to this important field of research.  
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APPENDIX A 
 
AMPLITUDES AND RATE CONSTANTS FOR AMIDE H/D EXCHANGE PROFILES 
 
Table 2. Amplitudes and rate constants for amide H/D exchange profiles in Figure 17. H/D 
exchange profiles for select peptides in 15-LOX-2 are shown in Figure 17 in the following states; 
(1) Ca2+ free 15-LOX-2 (blue),(2) Ca2+-15-LOX-2 (red), and (3) nanodisc-associated Ca2+-15-
LOX-2 (green). The data was fit to a sum of first-order rate terms, and the following values were 
calculated.  
 
 
 
 
  
 
 
Peptide/ State Afast (D) A1 (D) k1 (min
-1)
A 45-52
EGTA 2.2 1.41  0.24 0.015  0.005
Ca2+ 2.3 1.52  0.20 0.017  0.004
Ca2+ and ND 2.8 1.0  0.4 ≤ 1 x 10-4
B 54-66
EGTA 3.1 2.01  0.19 0.01  0.002
Ca2+ 3 2.02  0.23 0.009  0.002
Ca2+ and ND 3.1 1.79  0.30 0.001  0.001
C 67-87
EGTA 6 1.01  0.24 ≤ 1 x 10-4
Ca2+ 5.8 2 0.006   0.004
Ca2+ and ND 4.7 2.33  0.2 0.003  0.001
D 92-104
EGTA 2.7 0.48  0.09 0.0005  0.0002
Ca2+ 2.2 1.13  0.17 0.0007  0.0002
Ca2+ and ND 2.1 1.35  0.16 0.0006  0.0002
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Table 3. Amplitudes and rate constants for amide H/D exchange profiles in Figure 22. H/D 
exchange profiles for select peptides in 15-LOX-2 are shown in Figure 22 in the following states; 
(1) Ca2+-15-LOX-2 (blue); (2) Ca2+-15-LOX-2 with AA present (green); (3) Ca2+-15-LOX-2 with 
15-HpETE present (red); and (4) Ca2+-free 15-LOX-2 with AA present (black). The data was fit 
to a sum of first- or second-order rate terms, and the following values were calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide/ State Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min
-1)
A 185-191
Ca2+ 1.4 1.72  0.08 0.006  0.0009
Ca2+ and AA 0.7 0.60  0.24 0.007  0.001 1.26  0.38 ≤ 1 x 10-4
Ca2+ and 15-HpETE 0.5 1.16  0.07 0.007  0.001 1.45  0.3 ≤ 1 x 10-4
EGTA and AA 0.6 1.41  0.11 0.007  0.002 1.76  0.002 ≤ 1 x 10-5
B 419-438
Ca2+ 1.4 1.56  0.35 0.006  0.004 6.01  0.24 ≤ 1 x 10-5
Ca2+ and AA 1.0 0.96  0.14 0.005  0.002 1.92  0.35 ≤ 2 x 10-4
Ca2+ and 15-HpETE 0.9 0.58  0.29 0.004  0.004 1.37  0.32 ≤ 2 x 10-4
EGTA and AA 1.2 0.82  0.30 0.017  0.014 1.60  0.47 ≤ 2 x 10-4
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Table 4. Amplitudes and rate constants for amide H/D exchange profiles in Figure 23. H/D 
exchange profiles for select peptides in 15-LOX-2 are shown in Figure 23 in the following states; 
(1) Ca2+-15-LOX-2 (blue); (2) Ca2+-15-LOX-2 with AA present (green); (3) Ca2+-15-LOX-2 with 
15-HpETE present (red); and (4) Ca2+-free 15-LOX-2 with AA present (black).  The data was fit 
to a sum of first- or second-order rate terms, and the following values were calculated.  
 
 
 
 
 
 
 
 
 
 
 
Peptide/ State Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min
-1)
A 45-52
Ca2+ 1.21 1.51  0.2 0.017  0.004
Ca2+ and AA 0.82 0.68  0.25 0.006  0.005 1.38  0.30 ≤ 3 x 10-4
Ca2+ and 15-HpETE 0.43 0.76  0.11 0.021  0.006 1.32  0.010 ≤ 1 x 10-4
EGTA and AA 0.75 2.55  0.63 0.023  0.009 1.6  0.015 ≤ 1 x 10-5
B 54-66
Ca2+ 3.1 2.02  0.23 0.009  0.002 4.02  0.09 ≤ 1 x 10-6
Ca2+ and AA 1.4 3.3  0.19 0.004  0.0008 4.02  0.12 ≤ 1 x 10-6
Ca2+ and 15-HpETE 1.2 3.8  0.25 0.003  0.0006 3.99  0.18 ≤ 1 x 10-6
EGTA and AA 1.6 3.04  0.25 0.003  0.001 4.3  0.17 ≤ 1 x 10-6
C 67-87
Ca2+ 5.8 1.01  0.24 0.0061  0.004 2.33  0.13 ≤ 1 x 10-5
Ca2+ and AA 2.0 2.76  0.36 0.002  0.0008 3.69  0.30 ≤ 1 x 10-5
Ca2+ and 15-HpETE 1.6 3.73  0.15 0.0022  0.0002 3.62  0.3 ≤ 1 x 10-6
EGTA and AA 2.2 3.10  0.25 0.0045  0.0010 3.49  0.15 ≤ 1 x 10-6
 117 
 
Table 5. Amplitudes and rate constants for amide H/D exchange profiles in Figure 23. H/D 
exchange profiles for select peptides in 15-LOX-2 are shown in Figure 23 in the following states; 
(1) Ca2+-15-LOX-2 (blue); (2) Ca2+-15-LOX-2 and AA present (green); (3) Ca2+-15-LOX-2 and 
15-HpETE present (red); and (4) Ca2+-15-LOX-2 and 13-HODE present (black).  The data was fit 
to a sum of first- or second-rate terms, and the following values were calculated.  
Peptide/ State Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min
-1)
A 45-52
Ca2+ 1.21 1.51  0.2 0.017  0.004
Ca2+ and AA 0.82 0.68  0.25 0.006  0.005 1.38  0.30 ≤ 4 x 10-4
Ca2+ and 15-HpETE 0.43 0.76  0.11 0.021  0.006 1.32  0.010 ≤ 1 x 10-4
Ca2+ and 13-HODE 1.8 1.62  0.23 0.006  0.002 0.81  0.12 ≤ 1 x 10-6
B 54-66
Ca2+ 3.1 2.02  0.23 0.009  0.002 4.02  0.09 ≤ 1 x 10-6
Ca2+ and AA 1.4 3.3  0.19 0.004  0.0008 4.02  0.12 ≤ 1 x 10-6
Ca2+ and 15-HpETE 1.2 3.8  0.25 0.003  0.0006 3.99  0.18 ≤ 1 x 10-6
Ca2+ and 13-HODE 1.2 2.55  0.19 0.01  0.001 3.85  0.07 ≤ 1 x 10-6
C 67-87
Ca2+ 5.8 1.01  0.24 0.0061  0.004 2.33  0.13 ≤ 1 x 10-5
Ca2+ and AA 2.0 2.76  0.36 0.002  0.0008 3.69  0.30 ≤ 1 x 10-5
Ca2+ and 15-HpETE 1.6 3.73  0.15 0.0022  0.0002 3.62  0.30 ≤ 1 x 10-6
Ca2+ and 13-HODE 4 2.55  0.26 0.017  0.003 3.06  0.07 ≤ 1 x 10-5
D 92-104
Ca2+ 2.1 1.13  0.17 0.0008  0.0002
Ca2+ and AA 1.9 1.42  0.15 0.0007  0.0001
Ca2+ and 15-HpETE 1.7 0.78  0.16 0.0036  0.002
Ca2+ and 13-HODE 2.2 1.40  0.075 0.0010  0.001
E 117-134
Ca2+ 3.7 1.76  0.50 0.005  0.003 3.46  0.58 ≤ 7 x 10-4
Ca2+ and AA 2 3.87  0.36 0.010  0.002 3.55  0.23 ≤ 2 x 10-4
Ca2+ and 15-HpETE 2.9 3.62  0.61 0.013  0.02 2.88  0.32 ≤ 1 x 10-4
Ca2+ and 13-HODE 5.1 2.42  0.25 0.013  0.003 2.56  0.22 ≤ 8 x 10-4
F 185-191
Ca2+ 1.4 1.72  0.08 0.006  0.0009
Ca2+ and AA 0.7 0.60  0.24 0.007  0.001 1.26  0.38 ≤ 1 x 10-4
Ca2+ and 15-HpETE 0.5 1.16  0.07 0.007  0.001 1.45  0.3 ≤ 1 x 10-4
Ca2+ and 13-HODE 1.2 1.09  0.08 0.003  0.0009
G 419-438
Ca2+ 5.8 1.01  0.24 0.0061  0.004 2.33  0.13 ≤ 1 x 10-5
Ca2+ and AA 2.0 2.76  0.36 0.002  0.0008 3.69  0.30 ≤ 1 x 10-5
Ca2+ and 15-HpETE 1.6 3.73  0.15 0.0022  0.0002 3.62  0.30 ≤ 1 x 10-6
Ca2+ and 13-HODE 2.0 4.06  0.17 0.002  0.0002
H 672-676
Ca2+ 0.25 0.44  0.019 ≤ 8 x 10-4
Ca2+ and AA 0.4 0.50  0.10 ≤ 6 x 10-4
Ca2+ and 15-HpETE 0.6 0.49  0.06 ≤ 3 x 10-4
Ca2+ and 13-HODE 0.5 0.42  0.10 ≤ 2 x 10-4
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APPENDIX B 
 
ADDITIONAL H/D EXCHANGE PROFILES FOR 15-LOX-2 
 
Figure 38. H/D exchange kinetic profiles for 15-LOX-2 as a function of Ca2+ binding and 
nanodisc-association, Resides 1-364. The number of deuterons incorporated is plotted vs time for 
15-LOX-2 peptides analyzed but not directly discussed throughout this work. The following 15-
LOX-2 states are shown; (1) Ca2+ free 15-LOX-2 (blue squares), (2) Ca2+-15-LOX-2 (red circle), 
and (3) nanodisc-associated Ca2+-15-LOX-2 (green triangle). 
= 15-LOX-2 with EGTA
= 15-LOX-2 with Ca2+
= 15-LOX-2 with nanodisc  
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Figure 39. H/D exchange kinetic profiles for 15-LOX-2 as a function of Ca2+ binding and 
nanodisc-association, Resides 345-676. The number of deuterons incorporated is plotted vs time 
for 15-LOX-2 peptides analyzed but not directly discussed throughout this work. The following 
15-LOX-2 states are shown; (1) Ca2+ free 15-LOX-2 (blue squares), (2) Ca2+-15-LOX-2 (red 
circle), and (3) nanodisc-associated Ca2+-15-LOX-2 (green triangle). 
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Figure 40. H/D exchange kinetic profiles for 15-LOX-2 as a function of AA and 15-HpETE 
binding, Resides 1-354. The number of deuterons incorporated is plotted vs time for 15-LOX-2 
peptides analyzed but not directly discussed throughout this work. The following 15-LOX-2 states 
are shown; (1) Ca2+-15-LOX-2 (blue squares), (2) Ca2+-15-LOX-2 with AA present (green 
triangle), and (3) Ca2+-15-LOX-2 with 15-HpETE present (red circle). 
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Figure 41. H/D exchange kinetic profiles for 15-LOX-2 as a function of AA and 15-HpETE 
binding, Resides 345-676. The number of deuterons incorporated is plotted vs time for 15-LOX-
2 peptides analyzed but not directly discussed throughout this work. The following 15-LOX-2 
states are shown; (1) Ca2+-15-LOX-2 (blue squares), (2) Ca2+-15-LOX-2 with AA present (green 
triangle), and (3) Ca2+-15-LOX-2 with 15-HpETE present (red circle). 
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APPENDIX C 
 
SUPPLEMENTAL INFORMATION FOR CHAPTER III 
 
Figure 42. SDS-PAGE gel of 15-LOX-2 associated with nanodiscs. The fractions collected from 
the elution of nanodisc associated 15-LOX-2 from a HiLoad 16/60 Superdex 200 pg column 
(Figure 29) were analyzed by a SDS-PAGE gel. 1 mL fractions from the peak at 8.5 mL were used 
to determine the protein content. A band indicative of 15-LOX-2 (76 kDa) and a band indicative 
of the nanodisc scaffold protein (MSP1e3d1, 37 kDa) was observed, indicating that 15-LOX-2 is 
associated to nanodiscs. 
 
 
Figure 43. H/D exchange of 15-LOX-2 associated with nanodiscs containing AA. To determine 
if presence of substrate increases the “tightness” of membrane association nanodiscs composed of 
phospholipids and increasing concentration of AA were created and had 15-LOX-2 associated with 
them. H/D exchange was measured at 15 seconds. The similarities in deuterium incorporation 
between nanodisc associated soluble Ca2+-15-LOX-2 (green) and nanodisc associated Ca2+-15-
LOX-2 suggest AA presence does not affect 15-LOX-2 association.   
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APPENDIX D 
 
SUPPLEMENTAL INFORMATION FOR CHAPTER V 
 
Figure 44. HPLC chromatogram of LOX products. Product analysis of (A) Stable 5-LOX 
reveals that 5-HpETE is the major product of 5-LOX enzymatic oxygenation of AA. (B) Similar 
methods reveal that 15-LOX-2 primarily produces 15-HpETE upon AA oxygenation.   
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